U.S. patent application number 16/151781 was filed with the patent office on 2019-01-24 for use of interleukin-4 antagonists and compositions thereof.
This patent application is currently assigned to IMMUNEX CORPORATION. The applicant listed for this patent is IMMUNEX CORPORATION. Invention is credited to Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris, John D. Pluenneke.
Application Number | 20190023798 16/151781 |
Document ID | / |
Family ID | 27504940 |
Filed Date | 2019-01-24 |
![](/patent/app/20190023798/US20190023798A1-20190124-D00001.png)
![](/patent/app/20190023798/US20190023798A1-20190124-D00002.png)
![](/patent/app/20190023798/US20190023798A1-20190124-D00003.png)
![](/patent/app/20190023798/US20190023798A1-20190124-D00004.png)
![](/patent/app/20190023798/US20190023798A1-20190124-D00005.png)
![](/patent/app/20190023798/US20190023798A1-20190124-D00006.png)
United States Patent
Application |
20190023798 |
Kind Code |
A1 |
Armitage; Richard J. ; et
al. |
January 24, 2019 |
USE OF INTERLEUKIN-4 ANTAGONISTS AND COMPOSITIONS THEREOF
Abstract
Methods for treating medical conditions induced by interleukin-4
involve administering an IL-4 antagonist to a patient afflicted
with such a condition. Suitable IL-4 antagonists include, but are
not limited to, IL-4 receptors (such as a soluble human IL-4
receptor), antibodies that bind IL-4, antibodies that bind IL-4R,
IL-4 muteins that bind to IL-4R but do not induce a biological
response, molecules that inhibit IL-4-induced signal transduction,
and other compounds that inhibit a biological effect that results
from the binding of IL-4 to a cell surface IL-4R. Particular
antibodies provided herein include human monoclonal antibodies
generated by procedures involving immunization of transgenic mice.
Such human antibodies may be raised against human IL-4 receptor.
Certain of the antibodies inhibit both IL-4-induced and
IL-13-induced biological activities.
Inventors: |
Armitage; Richard J.;
(Bainbridge Island, WA) ; Escobar; Jose Carlos;
(Sammamish, WA) ; Morris; Arvia E.; (Seattle,
WA) ; Pluenneke; John D.; (Parkville, MO) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
IMMUNEX CORPORATION |
Thousand Oaks |
CA |
US |
|
|
Assignee: |
IMMUNEX CORPORATION
Thousand OaksThousand Oaks
CA
|
Family ID: |
27504940 |
Appl. No.: |
16/151781 |
Filed: |
October 4, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15893101 |
Feb 9, 2018 |
|
|
|
16151781 |
|
|
|
|
15414447 |
Jan 24, 2017 |
|
|
|
15893101 |
|
|
|
|
14175943 |
Feb 7, 2014 |
9587026 |
|
|
15414447 |
|
|
|
|
12829231 |
Jul 1, 2010 |
8679487 |
|
|
14175943 |
|
|
|
|
12291702 |
Nov 13, 2008 |
|
|
|
12829231 |
|
|
|
|
11588696 |
Oct 27, 2006 |
7465450 |
|
|
12291702 |
|
|
|
|
10324493 |
Dec 19, 2002 |
7186809 |
|
|
11588696 |
|
|
|
|
09847816 |
May 1, 2001 |
|
|
|
10324493 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 31/04 20180101;
C07K 16/28 20130101; C07K 14/7155 20130101; A61P 19/02 20180101;
C07K 16/2866 20130101; C07K 2317/76 20130101; A61K 38/00 20130101;
C07K 2317/565 20130101; A61P 11/06 20180101; A01K 2217/05 20130101;
A61K 2039/505 20130101; A61P 37/08 20180101; C07K 2317/56 20130101;
A61K 39/395 20130101; C07K 2317/21 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; A61K 39/395 20060101 A61K039/395; C07K 14/715 20060101
C07K014/715 |
Claims
1. An isolated anti-IL4 receptor antibody comprising a light-chain
variable region comprising the amino acid sequence of SEQ ID NO:6
and a heavy-chain variable region comprising the amino acid
sequence of SEQ ID NO:8.
2. The isolated antibody of claim 1, wherein said antibody: a)
antagonizes IL-4; or b) antagonizes IL-13; or c) antagonizes IL-4
and IL-13.
3. The isolated antibody of claim 1, wherein said antibody is a
monoclonal antibody.
4. The isolated antibody of claim 1, wherein said antibody is an
IgG antibody.
5. A nucleic acid that encodes the light-chain, the heavy-chain, or
the light-chain and the heavy-chain of the antibody of claim 1.
6. An isolated cell comprising the nucleic acid of claim 5.
7. The isolated cell of claim 6, wherein said cell is a
hybridoma.
8. The isolated cell of claim 6, wherein said cell is a recombinant
cell.
9. A method of manufacturing an antibody, comprising incubating the
isolated cell of claim 6 under conditions that allow it to express
an anti-IL4 receptor antibody comprising a light-chain variable
region comprising the amino acid sequence of SEQ ID NO:6 and a
heavy-chain variable region comprising the amino acid sequence of
SEQ ID NO:8 and isolating said antibody.
10. A method of treating an allergic disease, comprising
administering said antibody of claim 1 to a patient with said
allergic disease.
11. The method of claim 10, wherein said allergic disease is
allergic rhinitis, asthma, atopic dermatitis, or contact
dermatitis.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 15/893,101, filed Feb. 9, 2018, which is a continuation of U.S.
application Ser. No. 15/414,447, filed Jan. 24, 2017, abandoned,
which is a divisional of U.S. application Ser. No. 14/175,943,
filed Feb. 7, 2014, now U.S. Pat. No. 9,587,026, which is a
divisional of U.S. application Ser. No. 12/829,231, filed Jul. 1,
2010, now U.S. Pat. No. 8,679,487, which is a continuation of U.S.
application Ser. No. 12/291,702, filed Nov. 13, 2008, abandoned,
which is a continuation of U.S. application Ser. No. 11/588,696,
filed Oct. 27, 2006, now U.S. Pat. No. 7,465,450, which is a
divisional of U.S. application Ser. No. 10/324,493, filed Dec. 19,
2002, now U.S. Pat. No. 7,186,809, which is a continuation of U.S.
application Ser. No. 09/847,816, filed May 1, 2001, abandoned. The
above-identified applications are incorporated herein by
reference.
REFERENCE TO THE SEQUENCE LISTING
[0002] The present application is being filed along with a Sequence
Listing in electronic format via EFS-Web. The Sequence Listing is
provided as a text file entitled 3005-US-CNT5_SequenceListing.txt,
created Oct. 3, 2018, which is 55,606 bytes in size. The
information in the electronic format of the Sequence Listing is
incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
[0003] Interleukin-4 (IL-4), previously known as B cell stimulating
factor, or BSF-1, was originally characterized by its ability to
stimulate the proliferation of B cells in response to low
concentrations of antibodies directed to surface immunoglobulin.
IL-4 has been shown to possess a far broader spectrum of biological
activities, including growth co-stimulation of T cells, mast cells,
granulocytes, megakaryocytes, and erythrocytes. In addition, IL-4
stimulates the proliferation of several IL-2- and IL-3-dependent
cell lines, induces the expression of class II major
histocompatibility complex molecules on resting B cells, and
enhances the secretion of IgE and IgG1 isotypes by stimulated B
cells. IL-4 is associated with a TH2-type immune response, being
one of the cytokines secreted by TH2 cells.
[0004] Murine and human IL-4 have been identified and
characterized, including cloning of IL-4 cDNAs and determination of
the nucleotide and encoded amino acid sequences. (See Yokota et
al., Proc. Natl. Acad. Sci. USA 83:5894, 1986; Noma et al., Nature
319:640, 1986; Grabstein et al., J. Exp. Med. 163:1405, 1986; and
U.S. Pat. No. 5,017,691.)
[0005] IL-4 binds to particular cell surface receptors, which
results in transduction of a biological signal to cells such as
various immune effector cells. IL-4 receptors are described, and
DNA and amino acid sequence information presented, in Mosley et
al., Cell 59:335-348, Oct. 20, 1989 (murine IL-4R); Idzerda et al.,
J. Exp. Med. 171:861-873, March 1990 (human IL-4R); and U.S. Pat.
No. 5,599,905. The IL-4 receptor described in these publications is
sometimes referred to as IL-4R.alpha..
[0006] Other proteins have been reported to be associated with
IL-4R.alpha. on some cell types, and to be components of
multi-subunit IL-4 receptor complexes. One such subunit is
IL-2R.gamma., also known as IL-2R.gamma..sub.c. (See the discussion
of IL-4R complexes in Sato et al., Current Opinion in Cell Biology,
6:174-179, 1994.) IL-4R.alpha. has been reported to be a component
of certain multi-subunit IL-13 receptor complexes (Zurawski et al.,
J. Biol. Chem. 270 (23), 13869, 1995; de Vries, J. Allergy Clin.
Immunol. 102(2):165, August 1998; and Callard et al. Immunology
Today, 17(3):108, March 1996).
[0007] IL-4 has been implicated in a number of disorders, examples
of which are allergy and asthma. Studies of biological properties
of IL-4 continue, in an effort to identify additional activities
associated with this pleiotrophic cytokine, and to elucidate the
role IL-4 may play in various biological processes and
diseases.
SUMMARY OF THE INVENTION
[0008] The present invention provides methods for treating certain
conditions induced by IL-4, comprising administering an IL-4
antagonist to a patient afflicted with such a condition. Also
provided are compositions for use in such methods, comprising an
effective amount of an IL-4 antagonist and a suitable diluent,
excipient, or carrier. Endogenous IL-4 may be contacted with an
IL-4 antagonist in alternative methods, such as those involving ex
vivo procedures.
[0009] Among the conditions to be treated in accordance with the
present invention are septic arthritis, dermatitis herpetiformis,
chronic idiopathic urticaria, ulcerative colitis, scleroderma,
hypertrophic scarring, Whipple's Disease, benign prostate
hyperplasia, lung disorders in which IL-4 plays a role, conditions
in which IL-4-induced epithelial barrier disruption plays a role,
disorders of the digestive system in which IL-4 plays a role,
allergic reactions to medication, Kawasaki disease, sickle cell
crisis, Churg-Strauss syndrome, Grave's disease, pre-eclampsia,
Sjogren's syndrome, autoimmune lymphoproliferative syndrome,
autoimmune hemolytic anemia, Barrett's esophagus, autoimmune
uveitis, tuberculosis, and nephrosis. IL-4 antagonists also find
use as adjuvants to allergy immunotherapy and as vaccine
adjuvants.
[0010] IL-4 antagonists include, but are not limited to, IL-4
receptors (IL-4R), antibodies that bind IL-4, antibodies that bind
IL-4R, IL-4 muteins that bind to IL-4R but do not induce a
biological response, molecules that inhibit IL-4-induced signal
transduction, and other compounds that inhibit a biological effect
that results from the binding of IL-4 to a cell surface IL-4R.
[0011] Examples of IL-4 receptors are soluble forms of the human
IL-4 receptor of SEQ ID NO:2. Particular antibodies provided herein
include human monoclonal antibodies generated by procedures
involving immunization of transgenic mice. Such human antibodies
may be directed against human IL-4 receptor, for example.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIGS. 1A-C present the nucleotide sequence of the coding
region of a human IL-4 receptor cDNA. The amino acid sequence
encoded by the cDNA is presented as well. The cDNA clone was
isolated from a cDNA library derived from a human T cell line T22.
The encoded protein comprises (from N- to C-terminus) an N-terminal
signal peptide, followed by an extracellular domain, a
transmembrane region (underlined), and a cytoplasmic domain, as
discussed further below. The DNA and amino acid sequences of FIGS.
1A to 1C are also presented in SEQ ID NOS:1 and 2,
respectively.
[0013] FIGS. 2A-2C depict targeted insertion of a neo cassette into
the Sma I site of the .mu.1 exon. The construct was employed in
generating transgenic mice, as described in Example 2. FIG. 2A is a
schematic diagram of the genomic structure of the .mu. locus. The
filled boxes represent the p exons. FIG. 2B is a schematic diagram
of the CmD targeting vector. The dotted lines denote those genomic
.mu. sequences included in the construct. Plasmid sequences are not
shown. FIG. 2C is a schematic diagram of the targeted .mu. locus in
which the neo cassette has been inserted into .mu.1.
[0014] FIGS. 3A and 3B present the nucleotide sequence of a vector
designated pGP1k, as described in Example 3 below. This nucleotide
sequence also is presented in SEQ ID NO:4.
DETAILED DESCRIPTION OF THE INVENTION
[0015] The present invention provides methods for treating certain
conditions induced by IL-4, and for inhibiting biological
activities of interleukin-4 (IL-4) in vivo. One method comprises
administering an IL-4 antagonist to a patient afflicted with such a
condition. Compositions for use in such methods for treating
IL-4-induced conditions also are provided.
[0016] Among the conditions to be treated in accordance with the
present invention are septic/reactive arthritis, dermatitis
herpetiformis, chronic idiopathic urticaria, scleroderma,
hypertrophic scarring, Whipple's Disease, benign prostate
hyperplasia, lung disorders in which IL-4 plays a role, conditions
in which IL-4-induced epithelial barrier disruption plays a role,
disorders of the digestive system in which IL-4 plays a role,
including inflammatory bowel disease and other inflammatory
conditions in the gastrointestinal tract, allergic reactions to
medication, Kawasaki disease, sickle cell disease (including sickle
cell crisis), Churg-Strauss syndrome, Grave's disease,
pre-eclampsia, Sjogren's syndrome, autoimmune lymphoproliferative
syndrome, autoimmune hemolytic anemia, Barrett's esophagus,
autoimmune uveitis, tuberculosis, and nephrosis, as described in
more detail below. IL-4 antagonists also find use as adjuvants to
allergy immunotherapy and as vaccine adjuvants.
[0017] IL-4 antagonists that may be employed include those
compounds that inhibit a biological activity of IL-4. Biological
activity(ies) of IL-4 that are inhibited by an antagonist in
accordance with methods provided herein are activities that play a
role in the particular disease to be treated.
[0018] Suitable antagonists include, but are not limited to, IL-4
receptors (IL-4R), antibodies that bind IL-4, antibodies that bind
IL-4R, IL-4 muteins that bind to IL-4R but do not induce biological
responses, molecules that inhibit IL-4-induced signal transduction,
and other compounds that inhibit a biological effect that results
from the binding of IL-4 to a cell surface IL-4R. Examples of such
IL-4 antagonists are described in more detail below. Particular
embodiments of the invention are directed to novel antibodies,
polypeptides, and nucleic acid molecules, as described below.
Antibodies provided herein include, but are not limited to, human
monoclonal antibodies that bind to human IL-4 receptor, and that
function as antagonists of both IL-4 and IL-13.
Indications
[0019] The present invention provides methods comprising
administering an IL-4 antagonist to a patient afflicted with any of
a number of conditions induced by IL-4. IL-4-induced conditions
include conditions caused or exacerbated, directly or indirectly,
by IL-4. Other factors or cytokines also may play a role in such
conditions, but IL-4 induces or mediates the condition to some
degree, i.e., at least in part.
[0020] The biological activities of IL-4 are mediated through
binding to specific cell surface receptors, referred to as
interleukin-4 receptors (IL-4R). IL-4-induced conditions include
those arising from biological responses that result from the
binding of IL-4 to a native IL-4 receptor on a cell, or which may
be inhibited or suppressed by preventing IL-4 from binding to an
IL-4 receptor. Conditions that may be treated include, but are not
limited to, medical disorders characterized by abnormal or excess
expression of IL-4, or by an abnormal host response to IL-4
production. Further examples are conditions in which IL-4-induced
antibody production, or proliferation or influx of a particular
cell type, plays a role. IL-4-induced disorders include those in
which IL-4 induces upregulation of IL-4 receptors or enhanced
production of another protein that plays a role in a disease (e.g.,
another cytokine).
[0021] A method for treating a mammal, including a human patient,
who has such a medical disorder comprises administering an IL-4
antagonist to the mammal or otherwise contacting endogenous IL-4
with an antagonist, e.g., in an ex vivo procedure. Conditions that
may be treated in accordance with the present invention include,
but are not limited to, septic/reactive arthritis, dermatitis
herpetiformis, urticaria (especially chronic idiopathic urticaria),
ulcers, gastric inflammation, mucosal inflammation, ulcerative
colitis, Crohn's Disease, inflammatory bowel disease, other
disorders of the digestive system in which IL-4 plays a role (e.g.,
IL-4-induced inflammation of part of the gastrointestinal tract),
conditions in which IL-4-induced barrier disruption plays a role
(e.g., conditions characterized by decreased epithelial barrier
function in the lung or gastrointestinal tract), scleroderma,
hypertrophic scarring, Whipple's Disease, benign prostate
hyperplasia, IL-4-induced pulmonary conditions (including those
listed below), allergic reactions to medication, Kawasaki disease,
sickle cell disease or crisis, Churg-Strauss syndrome, Grave's
disease, pre-eclampsia, Sjogren's syndrome, autoimmune
lymphoproliferative syndrome, autoimmune hemolytic anemia,
Barrett's esophagus, autoimmune uveitis, tuberculosis, nephrosis,
pemphigus vulgaris or bullous pemphigoid (autoimmune blistering
diseases), and myasthenia gravis (an autoimmune muscular disease).
IL-4 antagonists also find use as adjuvants to allergy
immunotherapy and as vaccine adjuvants, especially when directing
the immune response toward a TH1 response would be beneficial in
treating or preventing the disease in question.
[0022] Septic/Reactive Arthritis
[0023] IL-4 antagonists may be employed in treating septic
arthritis, which also is known as reactive arthritis or bacterial
arthritis. Septic arthritis can be triggered by (result from, or
develop subsequent to) infection with such microbes as
Staphylococcus aureus, Chlamydia trachomatis, Yersinia e.g., Y.
enterocolitica, Salmonella, e.g., S. enteritidis, Shigella and
Campylobacter. S. aureus has been reported to be the major human
pathogen in septic arthritis, responsible for the majority of
cases.
[0024] IL-4 and IL-4-dependent Th2 responses play roles in
promoting septic arthritis. IL-4 antagonist(s) are employed in
accordance with the invention, to inhibit IL-4 and also to suppress
the Th2 response in patients having septic arthritis or at risk for
developing septic arthritis.
[0025] IL-4 increases bacterial burden and bacterial persistence in
joints, by inhibiting clearance of the bacteria. IL-4 antagonists
may be employed to assist in the clearance of bacteria associated
with reactive arthritis, thereby reducing clinical manifestations
such as swelling in joints. IL-4 antagonists may be administered to
a human patient afflicted with septic arthritis, to reduce
IL-4-mediated joint inflammation. In one approach, an antagonist is
injected into a joint, e.g., into synovial fluid in the knee.
[0026] The use of IL-4 antagonists may benefit patients having (or
at risk for) septic arthritis by suppressing a TH2 response and
promoting a TH1 response against the infection. TH2 cytokines may
contribute to bacterial persistence in the joint, whereas a TH1
response plays a role in eliminating the bacteria.
[0027] The antagonists may be administered to patients infected
with bacteria or other microbes such as those listed above, to
prevent development of septic arthritis. Antagonist(s) may be
administered after diagnosis with such an infection, but before
development of clinical symptoms of septic arthritis.
[0028] Whipple's Disease
[0029] Tropheryma whippelii is the causative bacterium for
Whipple's Disease, also known as intestinal lipodystrophy and
lipophagia granulomatosis. The disease is characterized by
steatorrhea, frequently generalized lymphadenopathy, arthritis,
fever, and cough. Also reported in Whipple's Disease patients are
an abundance of "foamy" macrophages in the jejunal lamina propria,
and lymph nodes containing periodic acid-schiff positive particles
appearing bacilliform by electron microscopy (Steadman's Medical
Dictionary, 26.sup.th Edition, Williams & Wilkins, Baltimore,
Md., 1995).
[0030] The use of IL-4 antagonist(s) may benefit patients having
(or at risk for developing) Whipple's Disease, by restoring a
normal balance between the TH1 and TH2 components of the patient's
immune response. Increased production of IL-4 (a TH2-type cytokine)
and decreased levels of certain TH1-type cytokines have been
associated with Whipple's Disease. TH2 cytokines may contribute to
bacterial persistence, whereas a TH1 response plays a role in
clearing the causative bacteria. IL-4 antagonists may be
administered to patients infected with T. whippelii, whether or not
the patient exhibits clinical symptoms of Whipple's Disease.
[0031] Dermatitis Herpetiformis
[0032] Dermatitis herpetiformis, also known as Duhring's disease,
is a chronic skin condition characterized by blistering skin
lesions, cutaneous IgA deposits, and itching. Patients have an
immunobullous skin disorder with an associated gluten sensitive
enteropathy, which is mediated by a Th2 immune response. IL-4
antagonist(s) are administered in accordance with the present
invention, to inhibit IL-4 and the Th2 response, thus promoting
healing of current lesions and reducing or preventing the formation
of blisters on the extensor body surfaces.
[0033] Hypertrophic Scarring
[0034] In accordance with the present invention, IL-4 antagonist(s)
are administered to patients who have, or are susceptible to
developing, hypertrophic scarring. In one method provided herein,
an IL-4 antagonist is administered to a burn patient. An immune
response to burns and other injury is believed to play a role in
the pathogenesis of hypertrophic scarring. Increased production of
TH2-type cytokines, including IL-4, and reduced levels of certain
TH1-type cytokines have been reported in burn patients who have
hypertropic scarring. The use of IL-4 antagonists may benefit
patients having (or at risk for developing) hypertrophic scarring,
by suppressing a TH2-type immune response.
[0035] Urticaria
[0036] Urticaria, especially chronic forms thereof such as chronic
idiopathic urticaria (CIU), may be treated with an IL-4 antagonist
in accordance with the present invention. CIU patients have higher
serum levels of IL-4 than controls, and may have a predominantly
TH2-type cytokine profile. Mast cells and Th2-type T cells are
implicated as primary effector cells in chronic urticaria. IL-4
stimulates mast cell proliferation. Mast cell degranulation leads
to histamine release, subsequent erythema, eosinophilia, redness of
skin, and itching. IL-4 antagonists are administered to inhibit
IL-4 and reduce the TH2-type response, thereby helping to control a
patient's urticaria.
[0037] Ulcerative Colitis; Other Disorders of the Gastrointestinal
Tract
[0038] IL-4 is implicated in the pathogenesis of ulcerative
colitis. Th2-type cytokines including IL-4 may predominate in the
colonic mucosa of patients with this disorder. The use of IL-4
antagonist(s) to suppress the TH2 response may alleviate this
condition.
[0039] In addition to ulcerative colitis, other disorders of the
gastrointestinal tract or digestive system may be treated with IL-4
antagonist(s). Examples of such disorders include, but are not
limited to, inflammatory bowel disease (IBD), with ulcerative
colitis and Crohn's Disease being forms of IBD, gastritis, ulcers,
and mucosal inflammation.
[0040] Any gastrointestinal condition in which IL-4 plays a role
may be treated with an IL-4 antagonist in accordance with the
present invention. For example, conditions involving IL-4-induced
inflammation of part of the gastrointestinal tract may be treated
with an IL-4 antagonist. Particular embodiments are directed to
treatment of chronic inflammatory conditions in the
gastrointestinal tract.
[0041] Other embodiments are directed to conditions in which
IL-4-induced barrier disruption plays a role, e.g., conditions
characterized by decreased epithelial barrier function in at least
a portion of the gastrointestinal tract. Such conditions may, for
example, involve damage to the epithelium that is induced by IL-4,
directly or indirectly.
[0042] The intestinal epithelium forms a relatively impermeable
barrier between the lumen and the submucosa. Disruption of the
epithelial barrier has been associated with conditions such as
inflammatory bowel disease. See the discussion in Youakim, A. and
M. Ahdieh (Am. J. Physiol. 276 (Gastrointest. Liver Physiol.
39):G1279-G1288, 1999), hereby incorporated by reference in its
entirety. A damaged or "leaky" barrier can allow antigens to cross
the barrier, which in turn elicits an immune response that may
cause further damage to gastrointestinal tissue. Such an immune
response may include recruitment of neutrophils or T cells, for
example. An IL-4 antagonist may be administered to inhibit
undesirable stimulation of an immune response.
[0043] Lung Disorders
[0044] Methods for treating IL-4-induced pulmonary disorders are
provided herein. Such disorders include, but are not limited to,
lung fibrosis, including chronic fibrotic lung disease, other
conditions characterized by IL-4-induced fibroblast proliferation
or collagen accumulation in the lungs, pulmonary conditions in
which a TH2-type immune response plays a role, conditions
characterized by decreased barrier function in the lung (e.g.,
resulting from IL-4-induced damage to the epithelium), or
conditions in which IL-4 plays a role in an inflammatory
response.
[0045] Cystic fibrosis is characterized by the overproduction of
mucus and development of chronic infections. Inhibiting IL-4 and
the Th2 response will reduce mucus production and help control
infections such as allergic bronchopulmonary aspergillosis
(ABPA).
[0046] Allergic bronchopulmonary mycosis occurs primarily in
patients with cystic fibrosis or asthma, where a Th2 immune
response is dominant. Inhibiting IL-4 and the Th2 response will
help clear and control these infections.
[0047] Chronic obstructive pulmonary disease is associated with
mucus hypersecrection and fibrosis. Inhibiting IL-4 and the Th2
response will reduce the production of mucus and the development of
fibrous thereby improving respiratory function and delaying disease
progression.
[0048] Bleomycin-induced pneumopathy and fibrosis, and
radiation-induced pulmonary fibrosis are disorders characterized by
fibrosis of the lung which is manifested by the influx of Th2, CD4
cells and macrophages, which produce IL-4 which in turn mediates
the development of fibrosis. Inhibiting IL-4 and the Th2 response
will reduce or prevent the development of these disorders.
[0049] Pulmonary alveolar proteinosis is characterized by the
disruption of surfactant clearance. IL-4 increases surfactant
product. Use of IL-4 antagonists will decrease surfactant
production and decrease the need for whole lung lavage.
[0050] Adult respiratory distress syndrome (ARDS) may be
attributable to a number of factors, one of which is exposure to
toxic chemicals. One patient population susceptible to ARDS is
critically ill patients who go on ventilators. ARDS is a frequent
complication in such patients. IL-4 antagonists may alleviate ARDS
by reducing inflammation and adhesion molecules, although methods
for treating such patients in accordance with the present invention
are not limited by a particular mechanism of action. IL-4
antagonists may be used to prevent or treat ARDS.
[0051] Sarcoidosis is characterized by granulomatus lesions. Use of
IL-4 antagonists to treat sarcoidosis, particularly pulmonary
sarcoidosis, is contemplated herein.
[0052] Conditions in which IL-4-induced barrier disruption plays a
role (e.g., conditions characterized by decreased epithelial
barrier function in the lung) may be treated with IL-4
antagonist(s). Damage to the epithelial barrier in the lungs may be
induced by IL-4 directly or indirectly. The epithelium in the lung
functions as a selective barrier that prevents contents of the lung
lumen from entering the submucosa. A damaged or "leaky" barrier
allows antigens to cross the barrier, which in turn elicits an
immune response that may cause further damage to lung tissue. Such
an immune response may include recruitment of eosinophils or mast
cells, for example. An IL-4 antagonist may be administered to
inhibit such undesirable stimulation of an immune response.
[0053] IL-4 antagonists may be employed to promote healing of lung
epithelium, thus restoring barrier function. IL-4 antagonists may
be employed to promote healing of lung epithelium in asthmatics,
for example. Alternatively, the antagonist is administered for
prophylactic purposes, to prevent IL-4-induced damage to lung
epithelium.
[0054] Tuberculosis
[0055] A TH2-type immune response is implicated in playing a role
in causing tissue damage (e.g., necrosis of lung tissue) in
tuberculosis (TB) patients. Elevated levels of IL-4 are associated
with TB. IL-4 production may be particularly elevated in cavitary
tuberculosis (i.e., in TB patients who have developed pulmonary
cavities, which can be detected/visualized by such techniques as
radiographs of the chest).
[0056] IL-4 antagonists may benefit TB patients (especially those
with cavitary TB) by suppressing a TH2-type immune response, or by
binding (and inactivating) excess secreted IL-4. Methods for
treating such patients in accordance with the present invention are
not limited by a particular mechanism of action, however. IL-4
antagonists advantageously are administered in an amount that
restores the desired balance between the TH1 and TH2 components of
the immune response, and reduces IL-4-induced tissue damage in a
patient.
[0057] Churg-Strauss Syndrome
[0058] Churg-Strauss syndrome, a disease also known as allergic
granulomatous angiitis, is characterized by inflammation of the
blood vessels in persons with a history of asthma or allergy, and
by eosinophilia. IL-4 antagonist(s) may be administered to
alleviate inflammation in patients with this syndrome. The use of
IL-4 antagonists to suppress a TH2-type immune response, and to
combat eosinophilia, would benefit the patients.
[0059] Pre-Eclampsia
[0060] Pre-eclampsia is a toxemia of late pregnancy. The condition
is characterized by a sharp rise in blood pressure, generally
accompanied by edema and albuminuria, during the third term of
pregnancy.
[0061] Elevated TH1-type and TH2-type immune responses may play a
role in the condition. One method provided herein comprises
administering an IL-4 antagonist to a pregnant woman who has
developed pre-eclampsia. The IL-4 antagonist is administered in an
amount, and for a period of time, sufficient to reduce the level of
IL-4 (or of TH2-type cytokines collectively) to a level that is
considered normal during pregnancy. In general, the IL-4 antagonist
is administered repeatedly throughout the duration of the
pregnancy.
[0062] Scleroderma
[0063] IL-4 antagonist(s) are administered to scleroderma patients
in accordance with the invention. The antagonists reduce
IL-4-induced collagen synthesis by fibroblasts in the patients. The
antagonists may be employed in preventing or reducing fibrosis in
skin and lung tissues, as well as other tissues in which fibrosis
occurs in scleroderma patients, suppressing collagen synthesis in
such tissues, and in treating scleroderma-related pulmonary
disease.
[0064] Benign Prostate Hyperplasia
[0065] Benign prostate hyperplasia (BPH), also known as benign
prostate hypertrophy, may be treated with IL-4 antagonist(s). While
not wishing to be bound by a particular mechanism of action,
administration of an IL-4 inhibitor may benefit a patient with BPH
by suppressing IL-4-induced inflammation, or by suppressing a
TH2-type immune response.
[0066] Grave's Disease
[0067] Antibodies directed against thyrotropin receptor play an
important role in Grave's Disease, a disorder characterized by
hyperthyroidism. Studies of cytokine production in Grave's Disease
patients show a shift toward a TH2-type cytokine response. Use of
an IL-4 antagonist to suppress the TH2-type immune response, and
suppress antibody production, would benefit Grave's Disease
patients.
[0068] Sickle Cell Disease
[0069] Sickle cell disease patients typically experience
intermittent periods of acute exacerbation called crises, with the
crises being categorized as anemic or vaso-occlusive. IL-4
antagonists find use in treating or preventing sickle cell crisis,
especially in patients with elevated IL-4 levels or in whom the
immune response has shifted toward a TH2-type response. Sickle cell
disease (especially sickle cell crisis) has been associated with
increased susceptibility to infectious diseases, including
bacterial infections. Administering IL-4 antagonists to sickle cell
disease patients may help the patient mount an immune response
against infectious diseases.
[0070] Sjogren's Syndrome
[0071] The autoimmune disease known as Sjogren's syndrome or sicca
syndrome typically combines dry eyes and dry mouth with a disorder
of the connective tissues, such as rheumatoid arthritis, lupus,
scleroderma, or polymyositis. The vast majority of patients are
middle age (or older) females. Sjogren's syndrome is an
inflammatory disease of glands (e.g., lacrimal and salivary glands)
and other tissues of the body. The syndrome typically is associated
with autoantibody production.
[0072] IL-4 antagonists may be administered to reduce the
inflammatory response (such as inflammation of glands, including
lacrimal glands) in such patients. IL-4 antagonists may benefit
Sjogren's syndrome patients by suppressing a TH2-type immune
response, or by binding (and inactivating) excess IL-4 at
inflammatory lesions. Methods for treating patients in accordance
with the present invention are not limited by a particular
mechanism of action, however.
[0073] Autoimmune Lymphoproliferative Syndrome
[0074] Manifestations of autoimmune lymphoproliferative syndrome
include lymphoproliferation and autoantibody production. Patients
with the syndrome reportedly have an inherited deficiency in
apoptosis. IL-4 antagonists may benefit patients with this syndrome
by suppressing a TH2-type immune response, or by binding (and
inactivating) excess IL-4 at sites of inflammation. Methods for
treating such patients in accordance with the present invention are
not limited by a particular mechanism of action, however.
[0075] Autoimmune Hemolytic Anemia
[0076] Excessive IL-4 secretion, and a deficiency in TH1-type
cytokines, are implicated in contributing to the pathogenesis of
autoimmune hemolytic anemia. IL-4 antagonists are administered in
accordance with the present invention, to benefit the patients by
reducing autoantibody production, and by restoring a more normal
balance between the TH1 and TH2 components of the immune
response.
[0077] Autoimmune Uveitis
[0078] Uveitis involves inflammation of the uvea (generally
considered to include the iris, ciliary body, and choroid,
considered together). Excess IL-4 secretion is implicated as
playing a role in pathogenesis of this sight-threatening
inflammatory eye disease. In accordance with the present invention,
IL-4 antagonist(s) are administered to a uveitis patient to reduce
disease severity. In one embodiment, IL-4 antagonist(s) are
administered to an individual who has autoimmune uveoretinitis.
[0079] Kawasaki Disease
[0080] Also known as the mucocutaneous lymph node syndrome,
Kawasaki disease (KD) mainly afflicts young children. The disease
is characterized by particular changes in the mucus membranes
lining the lips and mouth, and by enlarged, tender lymph glands.
Symptoms typically include fever, conjunctivitis, inflammation of
the lips and mucous membranes of the mouth, swollen glands in the
neck, and a rash covering the hands and feet, leading to hardened,
swollen and peeling skin on hands and feet. In children with
Kawasaki Disease (KD), inflammation of arteries (vasculitis) may
develop. Due to the effect of the disease on the vascular system,
KD reportedly is the main cause of acquired heart disease in
children.
[0081] IL-4 antagonists may be administered to patients with
Kawasaki Disease, to reduce the elevated levels of IL-4 in the
patient. Excessive IL-4 secretion and a deficiency in TH1-type
cytokines contribute to the pathogenesis of the disease.
[0082] Barrett's Esophagus
[0083] Barrett's esophagus is a condition characterized by
alteration (subsequent to irritation) of the cells in the
epithelial tissue that lines the lower portion of the esophagus.
Frequent reflux of the stomach contents into the esophagus, over
time, can lead to Barrett esophagus. Patients with Barrett
esophagus are at risk for developing esophageal cancer (e.g.,
adenocarcinoma). While not wishing to be bound by a particular
mechanism of action, administration of an IL-4 antagonist may
benefit a patient with Barrett's esophagus by suppressing a
TH2-type immune response. In one embodiment, an IL-4 antagonist is
administered to a patient with esophagitis, to inhibit progression
to Barrett's esophagus.
[0084] Nephrosis
[0085] Nephrosis, also known as nephrotic syndrome, is kidney
disease that is non-inflammatory and non-malignant. In the
condition known as minimal change nephrosis, glomerular damage
(believed to arise from structural changes in glomerular visceral
epithelial cells) results in abnormalities that include
proteinuria. A TH2-type immune response (especially secretion of
the TH2-type cytokines IL-4 and IL-13) are implicated as playing a
role in pathogenesis of minimal change nephrosis.
[0086] Other Indications
[0087] Additional examples of conditions that may be treated in
accordance with the present invention include but are not limited
to the following. IL-4 antagonists may be employed in treating or
preventing hyper IgE syndrome, idiopathic hypereosinophil syndrome,
allergic reactions to medication, autoimmune blistering diseases
(e.g., pemphigus vulgaris or bullous pemphigoid), myasthenia gravis
(an autoimmune muscular disease), and chronic fatigue syndrome.
IL-4 inhibitors may be employed in treating GVHD; particular
methods for treating GVHD combination therapy with other
therapeutic agents as described below. IL-4 inhibitors also find
use in treating or preventing hepatotoxicity induced by drugs such
as diclofenac (a non-steroidal anti-inflammatory drug).
[0088] An IL-4 antagonist may be employed as an adjuvant to allergy
immunotherapy treatment. IL-4 antagonists find further use as
vaccine adjuvants, such as adjuvants for cancer vaccines and
infectious disease vaccines. The use of IL-4 antagonists is
especially advantageous when favoring a TH1-type immune response
would be beneficial in preventing or treating the condition for
which the vaccine is being administered. IL-4 antagonists may be
employed when reducing an antibody-mediated immune response and/or
promoting a T-cell-mediated immune response is desired.
[0089] IL-4 Antagonists
[0090] IL-4 antagonists that may be employed in accordance with the
present invention include compounds that inhibit a biological
activity of IL-4. The IL-4-induced biological activities to be
inhibited by the methods provided herein are activities that
directly or indirectly play a role in the condition to be
treated.
[0091] Examples of IL-4 antagonists include, but are not limited
to, IL-4 receptors (IL-4R), antibodies, other IL-4-binding
molecules, and IL-4 muteins as discussed further below. The
antibodies may bind IL-4 or may bind an IL-4 receptor, for
example.
[0092] Antagonists that bind IL-4 include but are not limited to
IL-4 receptors and anti-IL-4 antibodies. Endogenous IL-4 that
becomes bound to such an antagonist is thereby prevented from
binding its natural receptor on cell surfaces in vivo, and thus
cannot manifest IL-4-mediated biological activities.
[0093] Different types of antagonists may act at different sites or
by different mechanisms of action. Examples include but are not
limited to antagonists that interfere with binding of IL-4 to cell
surface receptors or that inhibit signal transduction. The site of
action may be intracellular (e.g., by interfering with an
intracellular signaling cascade), on a cell surface, or
extracellular. Antagonists that act by interfering with the
interaction of IL-4 with IL-4R may bind to either IL-4 or to the
receptor. An antagonist need not completely inhibit an IL-4 induced
activity to find use in the present invention; rather, antagonists
that reduce a particular activity of IL-4 are contemplated for use
as well.
[0094] The above-presented discussions of particular mechanisms of
action for IL-4 antagonists in treating particular diseases are
illustrative only, and the methods presented herein are not bound
thereby. The mechanisms of action by which IL-4 antagonists
ameliorate diseases are not limited to those discussed above.
[0095] In treating particular disorders, an IL-4 antagonist may
reduce the amount of active IL-4 at a particular site within the
body that is involved in the disorder. Antagonists that bind IL-4
such that it no longer can bind to endogenous cellular receptors
functionally reduce the amount of active IL-4 available for
inducing biological responses.
[0096] An IL-4 antagonist may alleviate a disorder by reducing the
amount of free endogenous IL-4 that is circulating in the body,
e.g., in the bloodstream or in a particular tissue. When the action
of IL-4 on such tissue plays a role in pathogenesis of the disease,
the antagonist serves to block action of IL-4 in the tissue,
thereby alleviating the disorder. In a further example, antagonists
may inhibit IL-4-induced recruitment of cells to a site or tissue
within the body, wherein such recruitment plays a role in causing
or exacerbating a disease. The antagonists may inhibit an
IL-4-mediated influx of cells involved in an immune or inflammatory
response. An antagonist may act by reducing proliferation,
activation, migration, influx, or accumulation of a particular cell
type, or by inhibiting a biological response directly or indirectly
attributable to a particular cell type. Examples of particular cell
types are fibroblasts, mast cells, and eosinophils.
[0097] As discussed above, some conditions may be treated by
suppressing a TH2-type immune response. IL-4 is associated with a
TH2 response, and is one of the cytokines secreted by T-helper
cells of type 2 (TH2 cells). An IL-4 antagonist may be administered
to reduce a TH2-type immune response. The IL-4 antagonist may be
said to reduce proliferation of TH2 cells, to suppress a TH2
response, to shift the immune response toward a TH1 response, or to
favor a TH1-type response. The use of antagonists of other
cytokines associated with a TH2-type immune response is discussed
below. Antagonists of other TH2-type cytokine(s), such as IL-5,
IL-10, or IL-13, may be administered to patients who have a
disorder involving elevated levels of such cytokines. Techniques
for measuring the amount of such cytokines in a patient, e.g., in
the patient's serum, are well known.
[0098] One embodiment of the invention is directed to a method for
inhibiting IL-4-induced damage to epithelium, comprising
administering an IL-4 antagonist to an individual who has, or is at
risk of developing, a condition in which IL-4-mediated epithelial
barrier disruption plays a role. In accordance with the present
invention, barrier function studies revealed that IL-4 plays a role
in reduction of barrier function in models of lung epithelium and
intestinal epithelium, and that a soluble human IL-4 receptor
polypeptide (an IL-4 antagonist) inhibits the IL-4-mediated
reduction of barrier function (see example 7).
[0099] Particular embodiments of methods provided herein comprise
administering an IL-4 antagonist to inhibit IL-4-induced damage to
epithelium in the gastrointestinal tract or lung. Such methods may
be employed to prevent epithelial damage, or to restore epithelial
barrier function (i.e., promote repair or healing of the
epithelium). The ability of an IL-4 antagonist to inhibit
IL-4-induced damage to epithelium may be confirmed in any of a
number of suitable assays, such as those described in example 7
below.
[0100] Any inflammation associated with (or subsequent to) an
infection also may be treated with an IL-4 antagonist. The
antagonist may be administered to inhibit any IL-4-induced
component of an inflammatory response resulting from microbial
infection in the gastrointestinal tract, for example.
[0101] Combinations of two or more antagonists may be employed in
methods and compositions of the present invention. Examples of
suitable IL-4 antagonists are as follows.
[0102] IL-4 Receptor
[0103] A preferred IL-4 antagonist is an IL-4 receptor (IL-4R).
When administered in vivo, IL-4R polypeptides circulate in the body
and bind to circulating endogenous IL-4 molecules, preventing
interaction of IL-4 with endogenous cell surface IL-4 receptors,
thus inhibiting transduction of IL-4-induced biological
signals.
[0104] IL-4 receptors are described in U.S. Pat. No. 5,599,905;
Idzerda et al., J. Exp. Med. 171:861-873, March 1990 (human IL-4R);
and Mosley et al., Cell 59:335-348, Oct. 20, 1989 (murine IL-4R);
each of which is hereby incorporated by reference. The protein
described in those three references is sometimes referred to in the
scientific literature as IL-4R.alpha.. Unless otherwise specified,
the terms "IL-4R" and "IL-4 receptor" as used herein encompass this
protein in various forms that are capable of functioning as IL-4
antagonists, including but not limited to soluble fragments, fusion
proteins, oligomers, and variants that are capable of binding IL-4,
as described in more detail below.
[0105] The nucleotide sequence of a human IL-4R cDNA, and the amino
acid sequence encoded thereby, are set forth in FIGS. 1A-1C. The
cDNA clone was isolated from a cDNA library derived from a
CD4.sup.+/CD8.sup.- human T cell clone designated T22, as described
in Idzerda et al., J. Exp. Med., 171:861, March 1990, and in U.S.
Pat. No. 5,599,905, which are hereby incorporated by reference in
their entirety. The DNA and amino acid sequences of FIGS. 1A-1C are
presented in SEQ ID NO:1 and SEQ ID NO:2, respectively.
[0106] The encoded human IL-4R protein comprises (from N- to
C-terminus) an N-terminal signal peptide, followed by an
extracellular domain, a transmembrane region, and a cytoplasmic
domain. The transmembrane region, which is underlined in FIG. 1A,
corresponds to amino acids 208 through 231. The cytoplasmic domain
comprises amino acids 232 through 800.
[0107] A signal peptide includes amino acids -25 to -1 of SEQ ID
NO:2. An alternative signal peptide cleavage site occurs between
residues -3 and -2 of SEQ ID NO:2, such that the signal peptide
corresponds to residues -25 through -3.
[0108] As is recognized in the pertinent field, the signal peptide
cleavage site for a given protein may vary according to such
factors as the particular expression system (especially the host
cells) in which the protein is expressed. The exact boundaries of
the signal peptide, and thus the extracellular domain, of a given
recombinant protein thus may depend on the expression system
employed. Further, the signal peptide may be cleaved at more than
one position, generating more than one species of polypeptide in a
preparation of recombinant protein.
[0109] In one embodiment, in which an expression vector comprises
DNA encoding amino acids -25 through 207 of SEQ ID NO:2, the
expressed recombinant IL-4R includes two species of mature soluble
human IL-4R. The expressed polypeptides include a major species
corresponding to amino acids -2 to 207 and a minor species
corresponding to amino acids 1 to 207 of SEQ ID NO:2. Two alternate
forms of the extracellular domain of human IL-4R thus correspond to
residues -2 to 207 and 1 to 207 of SEQ ID NO:2. The term "mature"
refers to a protein in a form lacking a signal peptide or leader
sequence, as is understood in the pertinent art.
[0110] Among the IL-4 receptors suitable for use herein are IL-4R
fragments. Truncated IL-4R polypeptides may occur naturally, e.g.,
as a result of proteolytic cleavage, post-translational processing,
or alternative splicing of mRNA. Alternatively, fragments may be
constructed by deleting terminal or internal portions of an IL-4R
sequence, e.g., via recombinant DNA technology. Fragments that
retain the ability to bind IL-4 may be identified in conventional
binding assays. Such fragments may be soluble fragments, as
discussed below.
[0111] In a preferred embodiment of the invention, the antagonist
comprises a soluble form of the IL-4R. A soluble IL-4 receptor is a
polypeptide that is secreted from the cell in which it is
expressed, rather than being retained on the cell surface. The full
length human IL-4R protein of SEQ ID NO:2 is a transmembrane
protein, which, as described above, comprises an N-terminal signal
peptide, followed by an extracellular domain, a transmembrane
region, and a C-terminal cytoplasmic domain. Soluble IL-4R
polypeptides lack the transmembrane region that would cause
retention on the cell, and the soluble polypeptides consequently
are secreted into the culture medium. The transmembrane region and
intracellular domain of IL-4R may be deleted or substituted with
hydrophilic residues to facilitate secretion of the receptor into
the cell culture medium.
[0112] Particular embodiments of soluble IL-4R polypeptides lack
the transmembrane region but comprise the extracellular domain (the
complete extracellular domain or a fragment thereof that is capable
of binding IL-4). As one option, the polypeptide comprises all or
part of the cytoplasmic domain, as well as the extracellular domain
(or fragment of the extracellular domain), but lacks the
transmembrane region.
[0113] Examples of soluble human IL-4R polypeptides include, but
are not limited to, polypeptides comprising amino acid residues x
to y of SEQ ID NO:2, wherein x represents 1 or -2 and y represents
an integer from 197 to 207. Preferred embodiments include
polypeptides comprising residues 1 to 207 or -2 to 207 of SEQ ID
NO:2.
[0114] A protein preparation administered as an IL-4 antagonist may
comprise more than one form of IL-4R. For example, the preparation
may comprise polypeptide molecules consisting of amino acids 1 to
207 of SEQ ID NO:2, as well as polypeptides consisting of amino
acids -2 to 207 of SEQ ID NO:2.
[0115] IL-4R polypeptides arising from alternative mRNA constructs,
e.g., which can be attributed to different mRNA splicing events
following transcription, and which yield polypeptide translates
capable of binding IL-4, are among the IL-4R polypeptides disclosed
herein. Such alternatively spliced mRNAs may give rise to soluble
polypeptides.
[0116] Further examples of IL-4 receptors that may be employed in
the methods provided herein are variants having amino acid
sequences which are substantially similar to the native
interleukin-4 receptor amino acid sequence of SEQ ID NO:2, or
fragments thereof. Variant IL-4 receptor polypeptides that are
capable of functioning as IL-4 antagonists may be employed in the
methods of the present invention.
[0117] Any of a number of conventional assay techniques may be
employed to confirm that a given form of IL-4R (e.g., an IL-4R
fragment or variant) functions as an IL-4 antagonist. Examples
include binding assays or assays that test the ability of a given
IL-4R polypeptide to inhibit transduction of an IL-4-induced
biological signal. Examples of suitable in vitro assays are
described below.
[0118] "Substantially similar" IL-4 receptors include those having
amino acid or nucleic acid sequences that vary from a native
sequence by one or more substitutions, deletions, or additions, but
retain a desired biological activity of the IL-4R protein. Examples
of nucleic acid molecules encoding IL-4 receptors include, but are
not limited to: (a) DNA derived from the coding region of a native
mammalian IL-4R gene; (b) DNA that is capable of hybridization to a
DNA of (a) under moderately stringent conditions and which encodes
an IL-4R having a biological activity of a native IL-4R; or (c) DNA
that is degenerate as a result of the genetic code to a DNA defined
in (a) or (b) and which encodes an IL-4R having a biological
activity of a native IL-4R. Due to code degeneracy, there can be
considerable variation in nucleotide sequences encoding the same
amino acid sequence.
[0119] Variants may be naturally occurring, such as allelic
variants or those arising from alternative splicing of mRNA.
Alternatively, variants may be prepared by such well known
techniques as in vitro mutagenesis.
[0120] A variant sequence identified by Idzerda et al., supra,
comprises a GTC codon encoding the amino acid valine (Val) at
position 50, instead of isoleucine (lile). The variant sequence is
otherwise identical to the sequence of SEQ ID NOS:1 and 2. IL-4R
fragments, such as soluble fragments, comprising Val at position 50
are provided herein.
[0121] In particular embodiments, an IL-4 receptor DNA or amino
acid sequence is at least 80 percent identical to the sequence of a
native IL-4R. Preferably, an IL-4R DNA or polypeptide comprises a
sequence that is at least 90 percent identical to a native IL-4R
DNA or amino acid sequence. One example is a human IL-4R comprising
an amino acid sequence that is at least 80 percent identical to the
sequence presented in SEQ ID NO:2. Another example is a soluble
IL-4R comprising an amino acid sequence at least 80 percent
identical to the sequence of the extracellular domain of human
IL-4R. Further examples are polypeptides comprising amino acid
sequences that are at least 90 percent identical to the sequence
presented in SEQ ID NO:2, or a fragment thereof. In a particular
embodiment, the polypeptide comprises no more than 10 amino acid
substitutions. IL-4R polypeptides that retain the ability to bind
IL-4 may be identified in conventional binding assays.
[0122] Percent similarity or percent identity may be determined,
for example, by comparing DNA or amino acid sequence information
using the GAP computer program, version 6.0, available from the
University of Wisconsin Genetics Computer Group (UWGCG). The GAP
program utilizes the alignment method of Needleman and Wunsch (J.
Mol. Biol. 48:443, 1970), as revised by Smith and Waterman (Adv.
Appl. Math. 2:482, 1981). Briefly, the GAP program defines
similarity as the number of aligned symbols (i.e., nucleotides or
amino acids) which are similar, divided by the total number of
symbols in the shorter of the two sequences. The preferred default
parameters for the GAP program include: (1) a unary comparison
matrix (containing a value of 1 for identities and 0 for
non-identities) for nucleotides, and the weighted comparison matrix
of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as
described by Schwartz and Dayhoff, ed., Atlas of Protein Sequence
and Structure, National Biomedical Research Foundation, pp.
353-358, 1979; (2) a penalty of 3.0 for each gap and an additional
0.10 penalty for each symbol in each gap; and (3) no penalty for
end gaps.
[0123] IL-4R polypeptides that vary from native proteins but
possess a desired property may be constructed by, for example,
substituting or deleting residues not needed for the particular
biological activity. Substitutions may be conservative
substitutions, such that a desired biological property of the
protein is retained. Amino acids may be replaced with residues
having similar physicochemical characteristics.
[0124] Cysteine residues can be deleted or replaced with other
amino acids to prevent formation of incorrect intramolecular
disulfide bridges upon renaturation. Other alterations of a native
sequence involve modification of adjacent dibasic amino acid
residues, to enhance expression in yeast host cells in which KEX2
protease activity is present.
[0125] The present invention also includes IL-4R with or without
associated native-pattern glycosylation. The glycosylation pattern
may vary according to the type of host cells in which the protein
is produced. Another option is inactivation of N-glycosylation
sites by site-specific mutagenesis. N-glycosylation sites in
eukaryotic proteins are characterized by the amino acid triplet
Asn-A.sub.1-Z, where A.sub.1 is any amino acid except Pro, and Z is
Ser or Thr. In this sequence, asparagine provides a side chain
amino group for covalent attachment of carbohydrate. Such a site
can be eliminated by substituting another amino acid for Asn or for
residue Z, deleting Asn or Z, or inserting a non-Z amino acid
between A.sub.1 and Z, or an amino acid other than Asn between Asn
and A.sub.1.
[0126] Oligonucleotide-directed site-specific mutagenesis
procedures can be employed to provide an altered gene having
particular codons altered according to the substitution, deletion,
or insertion required. Examples of techniques for making such
alterations are described in Walder et al. (Gene 42:133, 1986);
Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January
1985, 12-19); Smith et al. (Genetic Engineering: Principles and
Methods, Plenum Press, 1981); and U.S. Pat. Nos. 4,518,584 and
4,737,462.
[0127] IL-4 receptors that may be employed also include
derivatives, e.g., various structural forms of the primary protein
which retain a desired biological activity. Due to the presence of
ionizable amino and carboxyl groups, for example, an IL-4R protein
may be in the form of acidic or basic salts, or in neutral form.
Individual amino acid residues may also be modified by oxidation or
reduction. The primary amino acid structure may be modified by
forming covalent or aggregative conjugates with other chemical
moieties, such as glycosyl groups, lipids, phosphate, acetyl groups
and the like, or by creating amino acid sequence mutants. PEGylated
derivatives (modified with polyethylene glycol) are contemplated.
Covalent derivatives may be prepared by linking particular
functional groups to IL-4R amino acid side chains or at the N- or
C-termini. IL-4R derivatives may also be obtained by cross-linking
agents, such as M-maleimidobenzoyl succinimide ester and
N-hydroxysuccinimide, at cysteine and lysine residues. IL-4R
proteins may also be covalently bound through reactive side groups
to various insoluble substrates, such as cyanogen
bromide-activated, bisoxirane-activated,
carbonyldiimidazole-activated or tosyl-activated agarose
structures, or by adsorbing to polyolefin surfaces (with or without
glutaraldehyde cross-linking).
[0128] Other derivatives of IL-4R within the scope of this
invention include covalent or aggregative conjugates of IL-4R or
its fragments with other proteins or polypeptides, such as by
expression of recombinant fusion proteins comprising heterologous
polypeptides fused to the N-terminus or C-terminus of an IL-4R
polypeptide. For example, the conjugated peptide may be a
heterologous signal (or leader) polypeptide, e.g., the yeast
.alpha.-factor leader, or a peptide such as an epitope tag.
IL-4R-containing fusion proteins can comprise peptides added to
facilitate purification or identification of IL-4R (e.g.,
poly-His). Specific examples of poly-His fusion constructs that is
biologically active are soluble human IL-4R (e.g., comprising
residues -2 to 207 or 1-207 of SEQ ID NO:2) His His and soluble
human IL-4R His His His His His His. An amino acid sequence of IL-4
receptor can also be linked to the Flag.RTM. peptide
Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (SEQ ID NO:3) as
described in Hopp et al., Bio/Technology 6:1204, 1988, and U.S.
Pat. No. 5,011,912. The Flag.RTM. peptide is highly antigenic and
provides an epitope reversibly bound by a specific monoclonal
antibody, enabling rapid assay and facile purification of expressed
recombinant protein. Reagents useful for preparing fusion proteins
in which the Flag.RTM. peptide is fused to a given polypeptide are
commercially available (Sigma, St. Louis, Mo.).
[0129] Oligomers that contain IL-4R polypeptides may be employed as
IL-4 antagonists. Oligomers may be in the form of covalently-linked
or non-covalently-linked dimers, trimers, or higher oligomers.
Oligomers comprising two or more IL-4R polypeptides are
contemplated for use, with one example being a homodimer. Other
oligomers include heterodimers, heterotrimers, and the like, which
comprise an IL-4R polypeptide as well as at least one polypeptide
that is not derived from the IL-4R of SEQ ID NO:2.
[0130] One embodiment is directed to oligomers comprising multiple
IL-4R polypeptides joined via covalent or non-covalent interactions
between peptide moieties fused to the IL-4R polypeptides. Such
peptides may be peptide linkers (spacers), or peptides that have
the property of promoting oligomerization. Leucine zippers and
certain polypeptides derived from antibodies are among the peptides
that can promote oligomerization of IL-4R polypeptides attached
thereto, as described in more detail below.
[0131] In particular embodiments, the oligomers comprise from two
to four IL-4R polypeptides. The IL-4R moieties of the oligomer may
be in any of the forms described above, e.g., variants or
fragments. Preferably, the oligomers comprise soluble IL-4R
polypeptides.
[0132] As one alternative, an oligomer is prepared using
polypeptides derived from immunoglobulins. Preparation of fusion
proteins comprising certain heterologous polypeptides fused to
various portions of antibody-derived polypeptides (including the Fc
domain) has been described, e.g., by Ashkenazi et al. (PNAS USA
88:10535, 1991); Byrn et al. (Nature 344:677, 1990); and
Hollenbaugh and Aruffo ("Construction of Immunoglobulin Fusion
Proteins", in Current Protocols in Immunology, Suppl. 4, pages
10.19.1-10.19.11, 1992).
[0133] One embodiment of the present invention is directed to a
dimer comprising two fusion proteins created by fusing IL-4R to the
Fc region of an antibody. A gene fusion encoding the IL-4R/Fc
fusion protein is inserted into an appropriate expression vector.
IL-4R/Fc fusion proteins are expressed in host cells transformed
with the recombinant expression vector, and allowed to assemble
much like antibody molecules, whereupon interchain disulfide bonds
form between the Fc moieties to yield divalent IL-4R.
[0134] The term "Fc polypeptide" as used herein includes native and
mutein forms of polypeptides derived from the Fc region of an
antibody. Truncated forms of such polypeptides containing the hinge
region that promotes dimerization are also included. Fusion
proteins comprising Fc moieties (and oligomers formed therefrom)
offer the advantage of facile purification by affinity
chromatography over Protein A or Protein G columns.
[0135] One suitable Fc polypeptide, described in PCT application WO
93/10151 (hereby incorporated by reference), is a single chain
polypeptide extending from the N-terminal hinge region to the
native C-terminus of the Fc region of a human IgG1 antibody.
Another useful Fc polypeptide is the Fc mutein described in U.S.
Pat. No. 5,457,035 and in Baum et al., (EMBO J. 13:3992-4001,
1994). The amino acid sequence of this mutein is identical to that
of the native Fc sequence presented in WO 93/10151, except that
amino acid 19 has been changed from Leu to Ala, amino acid 20 has
been changed from Leu to Glu, and amino acid 22 has been changed
from Gly to Ala. The mutein exhibits reduced affinity for Fc
receptors.
[0136] In other embodiments, IL-4R may be substituted for the
variable portion of an antibody heavy or light chain. If fusion
proteins are made with both heavy and light chains of an antibody,
it is possible to form an oligomer with as many as four IL-4R
extracellular regions.
[0137] Soluble recombinant fusion proteins comprising an IL-4R and
various portions of the constant region of an immunoglobulin are
described in EP 464,533, along with procedures for preparing such
fusion proteins and dimers thereof. Among the fusion proteins
described in EP 464,533 are those comprising the extracellular
portion of human IL-4R and an Fc polypeptide.
[0138] Alternatively, the oligomer is a fusion protein comprising
multiple IL-4R polypeptides, with or without peptide linkers
(spacer peptides). Among the suitable peptide linkers are those
described in U.S. Pat. Nos. 4,751,180 and 4,935,233.
[0139] Another method for preparing oligomeric IL-4R involves use
of a leucine zipper. Leucine zipper domains are peptides that
promote oligomerization of the proteins in which they are found.
Leucine zippers were originally identified in several DNA-binding
proteins (Landschulz et al., Science 240:1759, 1988), and have
since been found in a variety of different proteins. Among the
known leucine zippers are naturally occurring peptides and
derivatives thereof that dimerize or trimerize. Examples of leucine
zipper domains suitable for producing soluble oligomeric proteins
are described in PCT application WO 94/10308, and the leucine
zipper derived from lung surfactant protein D (SPD) described in
Hoppe et al. (FEBS Letters 344:191, 1994), hereby incorporated by
reference. The use of a modified leucine zipper that allows for
stable trimerization of a heterologous protein fused thereto is
described in Fanslow et al. (Semin. Immunol. 6:267-278, 1994). In
one approach, recombinant fusion proteins comprising a soluble
IL-4R polypeptide fused to a leucine zipper peptide are expressed
in suitable host cells, and the soluble oligomeric IL-4R that forms
is recovered from the culture supernatant.
[0140] One example of a heterodimer comprises an IL-4R polypeptide
derived from the human IL-4R of SEQ ID NO:2, and an IL-2R.gamma.
polypeptide. IL-2R.gamma. (also known as IL-2R.gamma..sub.c) is
described in U.S. Pat. No. 5,510,259 and in Takeshita et al.
(Science 257:379, 17 Jul. 1992), which are incorporated by
reference herein. The polypeptides may be in one of the various
forms described herein, e.g., soluble fragments, variants, and the
like, derived from the indicated proteins. One embodiment of such a
heterodimer comprises a soluble IL-4R/Fc fusion protein and a
soluble IL-2R.gamma./Fc fusion protein. Such heterodimers are
described in WO 96/11213, along with IL-4R homodimers.
[0141] Other examples of heterodimers comprise an IL-4R subunit
(preferably a soluble fragment of the protein of SEQ ID NO:2) and
at least one IL-13 receptor subunit. IL-13 receptor (IL-13R)
complexes and IL-13R polypeptides (such as polypeptides designated
IL-13R.alpha.1 and IL-13R.alpha.2) are described in Zurawski et
al., J. Biol. Chem. 270 (23), 13869, 1995; de Vries, J. Allergy
Clin. Immunol. 102(2):165, August 1998; Callard et al. Immunology
Today, 17(3):108, March 1996, and U.S. Pat. No. 5,710,023, each of
which is incorporated by reference herein. In one embodiment, a
heterodimer comprises a soluble human IL-4R and a soluble IL-13R
(preferably a soluble form of the polypeptide described in U.S.
Pat. No. 5,710,023 or IL-13R.alpha.1). The components of
heterodimers may be any suitable form of the polypeptides that
retains the desired activity, such as fragments, variants, or
fusion proteins (e.g., fusions of soluble receptor polypeptides
with Fc polypeptides, leucine zipper peptides, peptide linkers, or
epitope tags).
[0142] IL-4 receptor polypeptides and fusion proteins described
herein may be prepared by any of a number of conventional
techniques. IL-4R polypeptides may be purified from cells that
naturally express the receptor (such as the cells discussed in Park
et al., Proc. Natl. Acad. Sci. USA 84:1669-673, 1987), or may be
produced in recombinant expression systems, using well known
techniques. Expression systems for use in producing IL-4R include
those described in U.S. Pat. No. 5,599,905, which is hereby
incorporated by reference.
[0143] A variety of expression systems are known for use in
producing recombinant proteins. In general, host cells are
transformed with a recombinant expression vector that comprises DNA
encoding a desired IL-4R polypeptide. Among the host cells that may
be employed are prokaryotes, yeast or higher eukaryotic cells.
Prokaryotes include gram negative or gram positive organisms, for
example E. coli or bacilli. Higher eukaryotic cells include insect
cells and established cell lines of mammalian origin. Examples of
suitable mammalian host cell lines include the COS-7 line of monkey
kidney cells (ATCC CRL 1651) (Gluzman et al., Cell 23:175, 1981), L
cells, 293 cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese
hamster ovary (CHO) cells, HeLa cells, BHK (ATCC CRL 10) cell
lines, and the CVI/EBNA cell line derived from the African green
monkey kidney cell line CVI (ATCC CCL 70) as described by McMahan
et al. (EMBO J. 10: 2821, 1991). Appropriate cloning and expression
vectors for use with bacterial, fungal, yeast, and mammalian
cellular hosts are described by Pouwels et al. (Cloning Vectors: A
Laboratory Manual, Elsevier, New York, 1985).
[0144] The transformed cells are cultured under conditions that
promote expression of the IL-4R, and the polypeptide is recovered
by conventional protein purification procedures. One such
purification procedure includes the use of affinity chromatography,
e.g., over a matrix having IL-4 bound thereto. Expressed IL-4R will
be deposited in the cell membrane or secreted into the culture
supernatant, depending on the IL-4R DNA selected. Polypeptides
contemplated for use herein include substantially homogeneous
recombinant mammalian IL-4R polypeptides substantially free of
contaminating endogenous materials.
[0145] Antibodies
[0146] Antibodies that function as IL-4 antagonists may be employed
in the methods of the present invention. The antibodies preferably
are monoclonal antibodies or antigen-binding fragments thereof.
Advantageously, humanized or chimeric monoclonal antibodies are
employed. Most preferred are human monoclonal antibodies prepared
using transgenic mice, as described below.
[0147] Examples of suitable antibodies are those that interfere
with the binding of IL-4 to an IL-4 receptor. Such antibodies,
referred to herein as blocking antibodies, may be raised against
either IL-4 or IL-4R, and screened in conventional assays for the
ability to interfere with binding of IL-4 to IL-4 receptors.
Examples of suitable assays are assays that test the antibodies for
the ability to inhibit binding of IL-4 to cells expressing IL-4R,
or that test antibodies for the ability to reduce a biological or
cellular response that results from the binding of IL-4 to cell
surface IL-4 receptors.
[0148] It has been reported that IL-4R.alpha. is a component of
certain multi-subunit IL-13 receptor complexes (Zurawski et al., J.
Biol. Chem. 270 (23), 13869, 1995; de Vries, J. Allergy Clin.
Immunol. 102(2):165, August 1998; and Callard et al. Immunology
Today, 17(3):108, March 1996, each incorporated by reference
herein). Thus, some antibodies raised against IL-4R.alpha. may
interfere with the binding of IL-13 to such receptor complexes.
[0149] In one embodiment, antibodies directed against IL-4R block
binding of IL-4 and also IL-13 to cells. The antibodies inhibit
IL-4-induced biological activity and also inhibit IL-13-induced
activity, and thus may be employed in treating conditions induced
by either or both cytokines. Examples of such conditions include
but are not limited to IgE-mediated conditions, asthma, allergic
conditions, allergic rhinitis, and dermatitis including atopic
dermatitis.
[0150] Antibodies that bind to IL-4R and inhibit IL-4 binding may
be screened in various conventional assays to identify those
antibodies that also interfere with the binding of IL-13 to such
receptor complexes. Antibodies may be screened in binding assays or
tested for the ability to inhibit an IL-4-induced and an
IL-13-induced biological activity. An example of a suitable assay
is illustrated in Example 5 below.
[0151] Antibodies specific for IL-4 or IL-4R may be prepared by
well known procedures. See, for example, Monoclonal Antibodies,
Hybridomas: A New Dimension in Biological Analyses, Kennet et al.
(eds.), Plenum Press, New York (1980); and Antibodies: A Laboratory
Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y., (1988).
[0152] Antigen-binding fragments of such antibodies may be produced
by conventional techniques. Examples of such fragments include, but
are not limited to, Fab and F(ab').sub.2 fragments. Antibody
fragments and derivatives produced by genetic engineering
techniques are also contemplated for use. Unless otherwise
specified, the terms "antibody" and "monoclonal antibody" as used
herein encompass both whole antibodies and antigen-binding
fragments thereof.
[0153] Additional embodiments include chimeric antibodies, e.g.,
humanized versions of murine monoclonal antibodies. Such humanized
antibodies may be prepared by known techniques, and offer the
advantage of reduced immunogenicity when the antibodies are
administered to humans. In one embodiment, a humanized monoclonal
antibody comprises the variable region of a murine antibody (or
just the antigen binding site thereof) and a constant region
derived from a human antibody. Alternatively, a humanized antibody
fragment may comprise the antigen binding site of a murine
monoclonal antibody and a variable region fragment (lacking the
antigen-binding site) derived from a human antibody. Procedures for
the production of chimeric and further engineered monoclonal
antibodies include those described in Riechmann et al. (Nature
332:323, 1988), Liu et al. (PNAS 84:3439, 1987), Larrick et al.
(Bio/Technology 7:934, 1989), and Winter and Harris (TIPS 14:139,
May, 1993).
[0154] A method for producing an antibody comprises immunizing a
non-human animal, such as a transgenic mouse, with an IL-4R
polypeptide, whereby antibodies directed against the IL-4R
polypeptide are generated in said animal. Procedures have been
developed for generating human antibodies in non-human animals. The
antibodies may be partially human, or preferably completely human.
For example, transgenic mice into which genetic material encoding
one or more human immunoglobulin chains has been introduced may be
employed. Such mice may be genetically altered in a variety of
ways. The genetic manipulation may result in human immunoglobulin
polypeptide chains replacing endogenous immunoglobulin chains in at
least some (preferably virtually all) antibodies produced by the
animal upon immunization.
[0155] Mice in which one or more endogenous immunoglobulin genes
have been inactivated by various means have been prepared. Human
immunoglobulin genes have been introduced into the mice to replace
the inactivated mouse genes. Antibodies produced in the animals
incorporate human immunoglobulin polypeptide chains encoded by the
human genetic material introduced into the animal.
[0156] Examples of techniques for production and use of such
transgenic animals are described in U.S. Pat. Nos. 5,814,318,
5,569,825, and 5,545,806, which are incorporated by reference
herein. Examples 2-4 below provide further description of the
preparation of transgenic mice useful for generating human
antibodies directed against an antigen of interest.
[0157] Antibodies produced by immunizing transgenic non-human
animals with an IL-4R polypeptide are provided herein. Transgenic
mice into which genetic material encoding human immunoglobulin
polypeptide chain(s) has been introduced are among the suitable
transgenic animals. Examples of such mice include, but are not
limited to, those containing the genetic alterations described in
the examples below. One example of a suitable immunogen is a
soluble human IL-4R, such as a polypeptide comprising the
extracellular domain of the protein of SEQ ID NO:2, or other
immunogenic fragment of the protein of SEQ ID NO:2.
[0158] Monoclonal antibodies may be produced by conventional
procedures, e.g., by immortalizing spleen cells harvested from the
transgenic animal after completion of the immunization schedule.
The spleen cells may be fused with myeloma cells to produce
hybridomas, by conventional procedures.
[0159] A method for producing a hybridoma cell line comprises
immunizing such a transgenic animal with an IL-4R immunogen;
harvesting spleen cells from the immunized animal; fusing the
harvested spleen cells to a myeloma cell line, thereby generating
hybridoma cells; and identifying a hybridoma cell line that
produces a monoclonal antibody that binds an IL-4R polypeptide.
Such hybridoma cell lines, and anti-IL-4R monoclonal antibodies
produced therefrom, are encompassed by the present invention.
Monoclonal antibodies secreted by the hybridoma cell line are
purified by conventional techniques. Hybridomas or MAbs may be
further screened to identify MAbs with particular properties, such
as the ability to block an IL-4-induced activity, and to block an
IL-13-induced activity (see the assay in example 5).
[0160] Human antibodies that bind IL-4R are provided by the present
invention. In one embodiment of the invention, human antibodies
raised against IL-4R and produced by techniques involving use of
transgenic mice, block binding of IL-4 and also IL-13 to cells.
Such antibodies are IL-4 antagonists and additionally function as
IL-13 antagonists.
[0161] Among the uses of antibodies directed against an IL-4R is
use in assays to detect the presence of IL-4R polypeptides, either
in vitro or in vivo. The antibodies also may be employed in
purifying IL-4R proteins by immunoaffinity chromatography. Those
antibodies that additionally can block binding of IL-4 to IL-4R may
be used to inhibit a biological activity that results from such
binding. Blocking antibodies find use in the methods of the present
invention. Such antibodies which function as IL-4 antagonists may
be employed in treating any IL-4-induced condition, including but
not limited to asthma and allergies, e.g., allergic rhinitis,
contact dermatitis, and atopic dermatitis. In one embodiment, a
human anti-IL-4R monoclonal antibody generated by procedures
involving immunization of transgenic mice is employed in treating
such conditions.
[0162] Antibodies may be employed in an in vitro procedure, or
administered in vivo to inhibit an IL-4-induced biological
activity. Disorders caused or exacerbated (directly or indirectly)
by the interaction of IL-4 with cell surface IL-4 receptors thus
may be treated. A therapeutic method involves in vivo
administration of a blocking antibody to a mammal in an amount
effective for reducing an IL-4-induced biological activity.
[0163] Antibodies of the invention include, but are not limited to,
partially human (preferably fully human) monoclonal antibodies that
inhibit a biological activity of IL-4 and also inhibit a biological
activity of IL-13. One embodiment is directed to a human monoclonal
antibody that at least partially blocks binding of IL-4 to a cell,
and at least partially blocks binding of IL-13 to a cell.
[0164] Antibodies of the present invention include but are not
limited to antibodies generated by immunizing a transgenic mouse
with an IL-4 receptor immunogen, wherein the transgenic mouse is
selected from the mouse strains described in example 3 below. The
desired antibodies are at least partially human, and preferably
fully human. In one embodiment, the immunogen is a human IL-4
receptor polypeptide. Hybridoma cell lines derived from the
thus-immunized mice, wherein the hybridoma secretes a monoclonal
antibody that binds IL-4R, also are provided herein. Examples of
antibodies produced by immunizing such transgenic mice are the
human monoclonal antibodies designated 6-2 (described in example
6); 12B5 (described in example 8); and MAbs 63, 1B7, 5A1, and 27A1
(all described in example 9). Monoclonal antibodies 6-2, 12B5, 63,
1B7, 5A1, and 27A1 are fully human antibodies, and are capable of
inhibiting activity of both IL-4 and IL-13. MAbs 12B5, 63, and 1B7
are preferred antagonists of human IL-4 and human IL-13.
[0165] Particular monoclonal antibodies of the invention are
selected from the group consisting of MAb 6-2; a Mab that is
cross-reactive with 6-2; a MAb that binds to the same epitope as
6-2; a MAb that competes with 6-2 for binding to a cell that
expresses human IL-4R; a MAb that possesses a biological activity
of 6-2; and an antigen-binding fragment of any of the foregoing
antibodies. In one embodiment, the antibody has a binding affinity
for human IL-4R that is substantially equivalent to the binding
affinity of 6-2 for human IL-4R. MAb 6-2 is an IgM antibody. MAbs
of other isotypes (including but not limited to IgG1 and IgG4),
derived from 6-2, also are encompassed by the present invention.
Hybridoma cell lines that produce any such monoclonal antibodies
also are provided by the present invention.
[0166] One example of a biological activity of 6-2 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, a MAb of the invention possesses IL-4-blocking
activity substantially equivalent to that of 6-2; and possesses
IL-13-blocking activity substantially equivalent to that of 6-2.
Such activity may be measured in any suitable conventional assay
(e.g., as measured in the CD23 expression assay described in
example 5).
[0167] The DNA sequence of the variable region of the light chain
of MAb 6-2 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable region of the heavy chain of MAb 6-2 is presented as SEQ
ID NO:7, and the encoded amino acid sequence is presented in SEQ ID
NO:8. Antibodies of the present invention include, but are not
limited to, monoclonal antibodies that comprise, in their light
chain, residues 1 to 107 of SEQ ID NO:6; and antibodies that
additionally or alternatively comprise, in their heavy chain,
residues 1 to 118 of SEQ ID NO:8.
[0168] Complementarity determining regions (CDRs) of a given
antibody may be identified using the system described by Kabat et
al. in Sequences of Proteins of Immunological Interest, 5.sup.th
Ed., US Dept. of Health and Human Services, PHS, NIH, NIH
Publication no. 91-3242, 1991). Particular embodiments of
antibodies of the present invention comprise, within the variable
region of their light chain, at least one of the complementarity
determining regions (CDRs), or hypervariable regions, found in the
light chain of 6-2. CDRs of 6-2 are discussed in example 6. Thus,
among the antibodies provided herein are those comprising from one
to all three of the following sequences in the light chain variable
region: amino acid residues 24-35 of SEQ ID NO:6; residues 51-57 of
SEQ ID NO:6; and residues 90-97 of SEQ ID NO:6. Particular
antibodies provided herein comprise, within the variable region of
their heavy chain, at least one of the CDRs found in the heavy
chain of 6-2. Thus, among the antibodies provided herein are those
comprising from one to all three of the following sequences in the
heavy chain variable region: residues 31-35; residues 50-66; and
residues 99-107 of SEQ ID NO:8.
[0169] Particular monoclonal antibodies of the invention are
selected from the group consisting of MAb 12B5; a Mab that is
cross-reactive with 12B5; a MAb that binds to the same epitope as
12B5; a MAb that competes with 12B5 for binding to a cell that
expresses human IL-4R; a MAb that possesses a biological activity
of 12B5; and an antigen-binding fragment of any of the foregoing
antibodies. In one embodiment, the antibody has a binding affinity
for human IL-4R that is substantially equivalent to the binding
affinity of 12B5 for human IL-4R. MAb 12B5 is an IgG1 antibody.
MAbs of other isotypes, derived from 12B5, also are encompassed by
the present invention. In particular embodiments, the isotype of
the MAb is IgG1, IgG4, or IgM. Hybridoma cell lines that produce
any such monoclonal antibodies also are provided by the present
invention.
[0170] One example of a biological activity of 12B5 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, a MAb of the invention possesses IL-4-blocking
activity substantially equivalent to that of 12B5, and possesses
IL-13-blocking activity substantially equivalent to that of 12B5.
Such activity may be measured in any suitable conventional assay
(e.g., as measured in the CD23 expression assay described in
example 5).
[0171] IgG4 monoclonal antibodies derived from 12B5 are provided
herein. Another embodiment is directed to IgM monoclonal antibodies
derived from 12B5. Procedures for switching (altering) the subclass
or isotype of an antibody are known in the pertinent field. Such
procedures may involve, for example, recombinant DNA technology,
whereby DNA encoding antibody polypeptide chains that confer the
desired subclass is substituted for DNA encoding the corresponding
polypeptide chain of the parent antibody.
[0172] The DNA sequence of the variable region of the light chain
of MAb 12B5 is presented in SEQ ID NO:9, and the encoded amino acid
sequence is presented in SEQ ID NO:10. The DNA sequence for the
variable region of the heavy chain of MAb 12B5 is presented as SEQ
ID NO:11, and the encoded amino acid sequence is presented in SEQ
ID NO:12. Antibodies of the present invention include, but are not
limited to, monoclonal antibodies that comprise, in their light
chain, residues 1 to 109 of SEQ ID NO:10; and antibodies that
additionally or alternatively comprise, in their heavy chain,
residues 1 to 115 of SEQ ID NO:12.
[0173] Particular embodiments of antibodies of the present
invention comprise, within the variable region of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of 12B5.
CDRs of 12B5 are discussed in example 8. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable region: amino acid
residues 24-35 of SEQ ID NO:10; residues 51-57 of SEQ ID NO:10; and
residues 90-99 of SEQ ID NO:10. Particular antibodies provided
herein comprise, within the variable region of their heavy chain,
at least one of the CDRs found in the heavy chain of 12B5. Thus,
among the antibodies provided herein are those comprising from one
to all three of the following sequences in the heavy chain variable
region: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:12.
[0174] Particular monoclonal antibodies of the invention are
selected from the group consisting of MAb 27A1; a Mab that is
cross-reactive with 27A1; a MAb that binds to the same epitope as
27A1; a MAb that competes with 27A1 for binding to a cell that
expresses human IL-4R; a MAb that possesses a biological activity
of 27A1; and an antigen-binding fragment of any of the foregoing
antibodies. In one embodiment, the antibody has a binding affinity
for human IL-4R that is substantially equivalent to the binding
affinity of 27A1 for human IL-4R. 27A1 is an IgG1 antibody. MAbs of
other isotypes, derived from 27A1, also are encompassed by the
present invention. Hybridoma cell lines that produce any such
monoclonal antibodies also are provided by the present
invention.
[0175] One example of a biological activity of 27A1 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, a MAb of the invention possesses IL-4-blocking
activity substantially equivalent to that of 27A1; and possesses
IL-13-blocking activity substantially equivalent to that of 27A1.
Such activity may be measured in any suitable conventional assay
(e.g., as measured in the CD23 expression assay described in
example 5).
[0176] The DNA sequence of the variable region of the light chain
of MAb 27A1 is presented in SEQ ID NO:13, and the encoded amino
acid sequence is presented in SEQ ID NO:14. The DNA sequence for
the variable region of the heavy chain of MAb 27A1 is presented as
SEQ ID NO:15, and the encoded amino acid sequence is presented in
SEQ ID NO:16. Antibodies of the present invention include, but are
not limited to, monoclonal antibodies that comprise, in their light
chain, residues 1 to 109 of SEQ ID NO:14; and antibodies that
additionally or alternatively comprise, in their heavy chain,
residues 1 to 116 of SEQ ID NO:16.
[0177] Particular embodiments of antibodies of the present
invention comprise, within the variable region of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of 27A1.
CDRs of 27A1 are discussed in example 9. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable region: amino acid
residues 24-35 of SEQ ID NO:14; residues 51-57 of SEQ ID NO:14; and
residues 90-99 of SEQ ID NO:14. Particular antibodies provided
herein comprise, within the variable region of their heavy chain,
at least one of the CDRs found in the heavy chain of 27A1. Thus,
among the antibodies provided herein are those comprising from one
to all three of the following sequences in the heavy chain variable
region: residues 31-35; residues 50-66; and residues 99-105 of SEQ
ID NO:16.
[0178] Particular monoclonal antibodies of the invention are
selected from the group consisting of MAb 5A1; a Mab that is
cross-reactive with 5A1; a MAb that binds to the same epitope as
5A1; a MAb that competes with 5A1 for binding to a cell that
expresses human IL-4R; a MAb that possesses a biological activity
of 5A1; and an antigen-binding fragment of any of the foregoing
antibodies. In one embodiment, the antibody has a binding affinity
for human IL-4R that is substantially equivalent to the binding
affinity of 5A1 for human IL-4R. 5A1 is an IgG1 antibody. MAbs of
other isotypes, derived from 5A1, also are encompassed by the
present invention. Hybridoma cell lines that produce any such
monoclonal antibodies also are provided by the present
invention.
[0179] One example of a biological activity of 5A1 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, a MAb of the invention possesses IL-4-blocking
activity substantially equivalent to that of 5A1; and possesses
IL-13-blocking activity substantially equivalent to that of 5A1.
Such activity may be measured in any suitable conventional assay
(e.g., as measured in the CD23 expression assay described in
example 5).
[0180] The DNA sequence of the variable region of the light chain
of MAb 5A1 is presented in SEQ ID NO:17, and the encoded amino acid
sequence is presented in SEQ ID NO:18. The DNA sequence for the
variable region of the heavy chain of MAb 5A1 is presented as SEQ
ID NO:19, and the encoded amino acid sequence is presented in SEQ
ID NO:20. Antibodies of the present invention include, but are not
limited to, monoclonal antibodies that comprise, in their light
chain, residues 1 to 107 of SEQ ID NO:18; and antibodies that
additionally or alternatively comprise, in their heavy chain,
residues 1 to 123 of SEQ ID NO:20.
[0181] Particular embodiments of antibodies of the present
invention comprise, within the variable region of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of 5A1.
CDRs of 5A1 are discussed in example 9. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable region: amino acid
residues 24-34 of SEQ ID NO:18; residues 50-56 of SEQ ID NO:18; and
residues 89-97 of SEQ ID NO:18. Particular antibodies provided
herein comprise, within the variable region of their heavy chain,
at least one of the CDRs found in the heavy chain of 5A1. Thus,
among the antibodies provided herein are those comprising from one
to all three of the following sequences in the heavy chain variable
region: residues 31-35; residues 50-65; and residues 98-112 of SEQ
ID NO:20.
[0182] Particular monoclonal antibodies of the invention are
selected from the group consisting of MAb 63; a Mab that is
cross-reactive with MAb 63; a MAb that binds to the same epitope as
63; a MAb that competes with 63 for binding to a cell that
expresses human IL-4R; a MAb that possesses a biological activity
of 63; and an antigen-binding fragment of any of the foregoing
antibodies. In one embodiment, the antibody has a binding affinity
for human IL-4R that is substantially equivalent to the binding
affinity of 63 for human IL-4R. MAb 63 is an IgM antibody. MAbs of
other isotypes, derived from 63, also are encompassed by the
present invention. Hybridoma cell lines that produce any such
monoclonal antibodies also are provided by the present
invention.
[0183] One example of a biological activity of 63 is the ability to
function as both an IL-4 antagonist and an IL-13 antagonist. In one
embodiment, a MAb of the invention possesses IL-4-blocking activity
substantially equivalent to that of 63; and possesses
IL-13-blocking activity substantially equivalent to that of 63.
Such activity may be measured in any suitable conventional assay
(e.g., as measured in the CD23 expression assay described in
example 5).
[0184] The DNA sequence of the variable region of the light chain
of MAb 63 is presented in SEQ ID NO:21, and the encoded amino acid
sequence is presented in SEQ ID NO:22. The DNA sequence for the
variable region of the heavy chain of MAb 63 is presented as SEQ ID
NO:23, and the encoded amino acid sequence is presented in SEQ ID
NO:24. Antibodies of the present invention include, but are not
limited to, monoclonal antibodies that comprise, in their light
chain, residues 1 to 107 of SEQ ID NO:22; and antibodies that
additionally or alternatively comprise, in their heavy chain,
residues 1 to 117 of SEQ ID NO:24.
[0185] Particular embodiments of antibodies of the present
invention comprise, within the variable region of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of 63.
CDRs of 63 are discussed in example 9. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable region: amino acid
residues 24-34 of SEQ ID NO:22; residues 50-56 of SEQ ID NO:22; and
residues 89-97 of SEQ ID NO:22. Particular antibodies provided
herein comprise, within the variable region of their heavy chain,
at least one of the CDRs found in the heavy chain of 63. Thus,
among the antibodies provided herein are those comprising from one
to all three of the following sequences in the heavy chain variable
region: residues 31-35; residues 50-66; and residues 99-106 of SEQ
ID NO:24.
[0186] Particular monoclonal antibodies of the invention are
selected from the group consisting of MAb 1B7; a Mab that is
cross-reactive with 1B7; a MAb that binds to the same epitope as
1B7; a MAb that competes with 1B7 for binding to a cell that
expresses human IL-4R; a MAb that possesses a biological activity
of 1B7; and an antigen-binding fragment of any of the foregoing
antibodies. In one embodiment, the antibody has a binding affinity
for human IL-4R that is substantially equivalent to the binding
affinity of 1B7 for human IL-4R. MAbs of other isotypes, derived
from 1B7, also are encompassed by the present invention. Hybridoma
cell lines that produce any such monoclonal antibodies also are
provided by the present invention.
[0187] One example of a biological activity of 1B7 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, a MAb of the invention possesses IL-4-blocking
activity substantially equivalent to that of 1B7; and possesses
IL-13-blocking activity substantially equivalent to that of 1B7.
Such activity may be measured in any suitable conventional assay
(e.g., as measured in the CD23 expression assay described in
example 5).
[0188] MAb 1B7 was derived from MAb 63. The amino acid sequence of
the heavy chain of MAb 1B7 is identical to that of MAb 63. The only
differences between the two antibodies are in the light chain. The
DNA sequence of the variable region of the light chain of MAb 1B7
is presented in SEQ ID NO:25, and the encoded amino acid sequence
is presented in SEQ ID NO:26. The DNA sequence for the variable
region of the heavy chain of MAb 1B7 is presented as SEQ ID NO:23,
and the encoded amino acid sequence is presented in SEQ ID NO:24
(same as for MAb 63). Antibodies of the present invention include,
but are not limited to, monoclonal antibodies that comprise, in
their light chain, residues 1 to 107 of SEQ ID NO:26; and
antibodies that additionally or alternatively comprise, in their
heavy chain, residues 1 to 117 of SEQ ID NO:24.
[0189] Particular embodiments of antibodies of the present
invention comprise, within the variable region of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of 1B7.
CDRs of 1B7 are discussed in example 9. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable region: amino acid
residues 24-34 of SEQ ID NO:26; residues 50-56 of SEQ ID NO:26; and
residues 89-97 of SEQ ID NO:26. Particular antibodies provided
herein comprise, within the variable region of their heavy chain,
at least one of the CDRs found in the heavy chain of 1B7. Thus,
among the antibodies provided herein are those comprising from one
to all three of the following sequences in the heavy chain variable
region: residues 31-35; residues 50-66; and residues 99-106 of SEQ
ID NO:24.
[0190] Derivatives of monoclonal antibodies directed against IL-4R
may be prepared, and screened for desired properties, by any of a
number of known techniques. Certain of the techniques involve
isolating DNA encoding a polypeptide chain (or portion thereof) of
a MAb of interest, and manipulating the DNA through recombinant DNA
technology. The DNA may be fused to another DNA of interest, or
altered (e.g., by mutagenesis or other conventional techniques) to
add, delete, or substitute one or more amino acid residues, for
example.
[0191] DNA encoding antibody polypeptides (e.g., heavy or light
chain, variable region only or full length) may be isolated from
B-cells of mice that have been immunized with IL-4R. The DNA may be
isolated by conventional procedures such as polymerase chain
reaction (PCR). Phage display is another example of a known
technique whereby derivatives of antibodies may be prepared. In one
approach, polypeptides that are components of an antibody of
interest are expressed in any suitable recombinant expression
system, and the expressed polypeptides are allowed to assemble to
form antibody molecules.
[0192] Single chain antibodies may be formed by linking heavy and
light chain variable region (Fv region) fragments via an amino acid
bridge (short peptide linker), resulting in a single polypeptide
chain. Such single-chain Fvs (scFvs) have been prepared by fusing
DNA encoding a peptide linker between DNAs encoding the two
variable region polypeptides (V.sub.L and V.sub.H). The resulting
antibody fragments can form dimers or trimers, depending on the
length of a flexible linker between the two variable domains (Kortt
et al., Protein Engineering 10:423, 1997). Techniques developed for
the production of single chain antibodies include those described
in U.S. Pat. No. 4,946,778; Bird (Science 242:423, 1988); Huston et
al. (Proc. Natl. Acad. Sci. USA 85:5879, 1988); and Ward et al.
(Nature 334:544, 1989). Single chain antibodies derived from
antibodies provided herein (including but not limited to scFvs
derived from MAbs 6-2, 12B5, 63, 1B7, 5A1, and 27A1) are
encompassed by the present invention.
[0193] Techniques are known for deriving an antibody of a different
subclass or isotype from an antibody of interest, i.e., subclass
switching. Thus, IgG1 or IgG4 monoclonal antibodies may be derived
from an IgM monoclonal antibody, for example, and vice versa. Such
techniques allow the preparation of new antibodies that possess the
antigen-binding properties of a given antibody (the parent
antibody), but also exhibit biological properties associated with
an antibody isotype or subclass different from that of the parent
antibody. Recombinant DNA techniques may be employed. Cloned DNA
encoding particular antibody polypeptides may be employed in such
procedures, e.g., DNA encoding the constant region of an antibody
of the desired isotype.
[0194] In particular embodiments, antibodies raised against IL-4R
have a binding affinity (Ka) for IL-4R of at least
1.times.10.sup.8. In other embodiments, the antibodies exhibit a Ka
of at least 1.times.10.sup.9 or at least 1.times.10.sup.10.
[0195] PEGylated derivatives of antibodies (modified with
polyethylene glycol) also are contemplated, and may be prepared by
conventional techniques. Also provided herein are conjugates
comprising a detectable (e.g., diagnostic) or therapeutic agent,
attached to an antibody directed against IL-4R. Examples of such
agents are well known, and include but are not limited to
diagnostic radionuclides, therapeutic radionuclides, and cytotoxic
drugs. The conjugates find use in in vitro or in vivo
procedures.
[0196] Particular embodiments of the invention are directed to
novel nucleic acid molecules and polypeptides. DNA and amino acid
sequence information has been determined for polypeptides that are
components of certain antibodies of the present invention, as
discussed in examples 6, 8, and 9 below. Among the nucleic acids of
the present invention is isolated DNA comprising a nucleotide
sequence selected from the group consisting of the nucleotide
sequence presented in SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, and SEQ ID NO:25. Among the polypeptides of
the present invention is a purified polypeptide comprising an amino
acid sequence selected from the group consisting of the amino acid
sequence presented in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ
ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20,
SEQ ID NO:22, SEQ ID NO:24, and SEQ ID NO:26. For in vivo use, the
polypeptides advantageously are purified. A polypeptide may be
purified individually, or in the form of a purified antibody of
which the polypeptide is a component.
[0197] Further examples of IL-4 antagonists are antibodies that
bind IL-4 and inhibit the binding of IL-4 to cell surface
receptors. Such antibodies may be prepared, and screened to
identify those that are blocking antibodies, by conventional
procedures. Antigen-binding fragments of such antibodies find use
as antagonists, as do humanized or genetically engineered
derivatives thereof.
[0198] Examples of procedures for preparing antibodies directed
against human IL-4 (including monoclonal antibodies), assays by
which blocking antibodies are identified, and techniques for
generating humanized or genetically engineered derivatives of
anti-IL-4 antibodies, are described in U.S. Pat. Nos. 5,041,381,
5,863,537, 5,928,904, and 5,676,940, which are hereby incorporated
by reference. Further examples of antibodies that may be employed
as IL-4 antagonists are described in WO 91/09059, also incorporated
by reference herein.
[0199] Other Antagonists
[0200] Any compound that functions as an IL-4 antagonist and is
suitable for administration in accordance with the methods of the
present invention may be employed. Antagonists need not completely
abolish IL-4-induced biological activity to be useful. Rather, a
given antagonist may reduce a biological activity of IL-4.
[0201] Derivatives, mutants/muteins, and other variants of IL-4
that function as IL-4 antagonists may be employed. Peptides (which
may or may not be muteins) derived from IL-4 that bind to an IL-4R
without inducing transduction of a biological signal find use
herein. Such peptides function as inert blockers, interfering with
the binding of biologically active endogenous IL-4 to cell surface
receptors. IL-4-induced signal transduction thereby is inhibited.
Muteins or other antagonists that induce a biological response at a
reduced level or to a lesser degree, compared to the response
induced by native IL-4, also find use as IL-4 antagonists.
[0202] Further examples of IL-4 antagonists, including IL-4
muteins, and procedures for preparation thereof are described in
Muller et al., J. Mol. Biol., 237:423-436, 1994; U.S. Pat. No.
6,028,176, and U.S. Pat. No. 5,723,118, which are each incorporated
by reference herein.
[0203] Other options are antisense molecules (oligonucleotides)
that inhibit expression of IL-4. Alternatively, the antisense
molecule may suppress expression of other molecules involved in
IL-4-induced signal transduction.
[0204] Any suitable assay, including in vitro assays, can be
utilized to determine whether a given compound inhibits an
IL-4-induced biological activity. An antagonist may be assayed for
the ability to inhibit .sup.3H-thymidine incorporation in cells
that normally proliferate in response to IL-4.
[0205] An alternative involves use of conventional binding assay
techniques to test an antagonist for the ability to inhibit binding
of IL-4 to cells expressing native or recombinant IL-4 receptors.
For use in such assays, recombinant human IL-4 can be expressed and
purified as described in U.S. Pat. No. 5,017,691, hereby
incorporated by reference herein, or in Park et al., J. Exp. Med.
166:476 (1987). The purified protein may be labeled with a
detectable agent (e.g., radiolabeled) by any of a number of
conventional techniques. A commercially available enzymobead
radioiodination reagent (BioRad) may be employed in radiolabeling
IL-4 with .sup.125I for example.
[0206] The ability of an IL-4 antagonist to inhibit IL-4-induced
damage to epithelium, such as lung epithelium or intestinal
epithelium (which may result in loss of barrier function), may be
confirmed in any of a number of suitable assays. Among the suitable
assay techniques are those described in example 7 below.
Therapeutic Methods and Administration of Antagonists
[0207] Methods provided herein comprise administering an IL-4
antagonist to a patient, thereby reducing an IL-4-induced
biological response that plays a role in a particular condition. In
particular embodiments, methods of the invention involve contacting
endogenous IL-4 with an IL-4 antagonist, e.g., in an ex vivo
procedure.
[0208] Treatment encompasses alleviation of at least one symptom of
a disorder, or reduction of disease severity, and the like. An
antagonist need not effect a complete "cure", or eradicate every
symptom or manifestation of a disease, to constitute a viable
therapeutic agent. As is recognized in the pertinent field, drugs
employed as therapeutic agents may reduce the severity of a given
disease state, but need not abolish every manifestation of the
disease to be regarded as useful therapeutic agents. One embodiment
of the invention is directed to a method comprising administering
to a patient an IL-4 antagonist in an amount and for a time
sufficient to induce a sustained improvement over baseline of an
indicator that reflects the severity of the particular
disorder.
[0209] Antibodies that inhibit the binding of both IL-4 and IL-13
to cells are discussed herein. A method for suppressing
IL-4-induced and IL-13-induced activities in humans comprises
administering an effective amount of such an antibody. Conditions
induced by IL-4 or by IL-13, or by both cytokines, thus may be
treated.
[0210] As is understood in the pertinent field, antagonists are
administered to a patient in a manner appropriate to the
indication. Antagonists may be administered by any suitable
technique, including but not limited to parenterally, topically, or
by inhalation. If injected, the antagonist can be administered, for
example, via intra-articular, intravenous, intramuscular,
intralesional, intraperitoneal or subcutaneous routes, by bolus
injection, or continuous infusion. Localized administration, e.g.
at a site of disease or injury is contemplated, as are transdermal
delivery and sustained release from implants. Delivery by
inhalation includes, for example, nasal or oral inhalation, use of
a nebulizer, inhalation of the antagonist in aerosol form, and the
like. Other alternatives include eyedrops; oral preparations
including pills, syrups, lozenges or chewing gum; and topical
preparations such as lotions, gels, sprays, and ointments.
[0211] Use of IL-4 antagonists in ex vivo procedures is
contemplated. For example, a patient's blood (bodily fluid
containing IL-4) may be contacted with an antagonist that binds
IL-4 ex vivo, thereby reducing the amount of IL-4 in the fluid when
returned to the patient. The antagonist may be bound to a suitable
insoluble matrix or solid support material.
[0212] Advantageously, antagonists are administered in the form of
a composition comprising at least one IL-4 antagonist and one or
more additional components such as a physiologically acceptable
carrier, excipient or diluent. The present invention provides such
compositions comprising an effective amount of an IL-4 antagonist,
for use in the methods provided herein.
[0213] The compositions contain antagonist(s) in any of the forms
described herein. The antagonist may be a whole antibody or an
antigen-binding fragment or engineered derivative thereof, for
example. For compositions containing an IL-4 receptor, the receptor
may be any of the fragments, variants, or oligomers of the protein
of SEQ ID NO:2 described herein, for example.
[0214] Compositions may, for example, comprise an antagonist
together with a buffer, antioxidant such as ascorbic acid, low
molecular weight polypeptide (such as those having fewer than 10
amino acids), protein, amino acid, carbohydrate such as glucose,
sucrose or dextrins, chelating agents such as EDTA, glutathione,
and other stabilizers and excipients. Neutral buffered saline or
saline mixed with conspecific serum albumin are examples of
appropriate diluents. In accordance with appropriate industry
standards, preservatives such as benzyl alcohol may also be added.
The composition may be formulated as a lyophilizate using
appropriate excipient solutions (e.g., sucrose) as diluents.
Suitable components are nontoxic to recipients at the dosages and
concentrations employed. Further examples of components that may be
employed in pharmaceutical formulations are presented in
Remington's Pharmaceutical Sciences, 16.sup.th Ed., Mack Publishing
Company, Easton, Pa., 1980.
[0215] Kits for use by medical practitioners include an IL-4
antagonist and a label or other instructions for use in treating
any of the conditions discussed herein. The kit preferably includes
a sterile preparation of one or more IL-4 antagonists, which may be
in the form of a composition as disclosed above, and may be in one
or more vials.
[0216] Dosages and the frequency of administration may vary
according to such factors as the route of administration, the
particular antagonist employed, the nature and severity of the
disease to be treated, whether the condition is acute or chronic,
and the size and general condition of the patient. Appropriate
dosages can be determined by procedures known in the pertinent art,
e.g. in clinical trials that may involve dose escalation
studies.
[0217] An antagonist may be administered once, or repeatedly. In
particular embodiments, the antagonist is administered over a
period of at least a month or more, e.g., for one, two, or three
months or even indefinitely. For treating chronic conditions,
long-term treatment is generally most effective. However, for
treating acute conditions, administration for shorter periods, e.g.
from one to six weeks, may be sufficient. In general, the
antagonist is administered until the patient manifests a medically
relevant degree of improvement over baseline for the chosen
indicator or indicators.
[0218] Particular embodiments of the present invention involve
administering an antagonist at a dosage of from about 1 ng/kg/day
to about 10 mg/kg/day, more preferably from about 500 ng/kg/day to
about 5 mg/kg/day, and most preferably from about 5 ug/kg/day to
about 2 mg/kg/day, to a patient. In additional embodiments, an
antagonist such as a soluble human IL-4R polypeptide is
administered to adults one time per week, two times per week, or
three or more times per week, to treat the medical disorders
disclosed herein. If injected, the effective amount of antagonist
per adult dose may range from 1-20 mg/m.sup.2, and preferably is
about 5-12 mg/m.sup.2. Alternatively, a flat dose may be
administered; the amount may range from 5-100 mg/dose. One range
for a flat dose is about 20-30 mg per dose. In one embodiment of
the invention, a flat dose of 25 mg/dose is repeatedly administered
by injection. If a route of administration other than injection is
used, the dose is appropriately adjusted in accordance with
standard medical practices. One example of a therapeutic regimen
involves injecting a dose of about 20-30 mg of IL-4R or other
antagonist one to three times per week over a period of at least
three weeks, though treatment for longer periods may be necessary
to induce the desired degree of improvement. For pediatric patients
(age 4-17), one suitable regimen involves the subcutaneous
injection of 0.4 mg/kg, up to a maximum dose of 25 mg of IL-4R,
administered two or three times per week.
[0219] Particular embodiments of the methods provided herein
involve subcutaneous injection of from 0.5 mg to 10 mg, preferably
from 3 to 5 mg, of a soluble IL-4R, once or twice per week. Another
embodiment is directed to pulmonary administration (e.g., by
nebulizer) of 3 or more mg of a soluble IL-4R once a week.
[0220] Examples of therapeutic regimens provided herein comprise
subcutaneous injection of a soluble human IL-4R once a week, at a
dose of 1.5 to 3 mg, to treat pulmonary sarcoidosis, minimal change
nephrosis, autoimmune uveitis, sickle cell crisis, Churg-Strauss
syndrome, Sjogren's syndrome, autoimmune lymphoproliferative
syndrome, pre-eclampsia, autoimmune hemolytic anemia, Barrett's
esophagus, Grave's Disease, Kawasaki Disease, and cavitary
buberculosis. Weekly administration of IL-4R is continued until
symptoms subside. Treatment may resume as needed, or,
alternatively, maintenance doses may be administered.
[0221] An antagonist is administered to the patient in an amount
and for a time sufficient to induce an improvement, preferably a
sustained improvement, in at least one indicator that reflects the
severity of the disorder that is being treated. Various indicators
that reflect the extent of the patient's illness may be assessed
for determining whether the amount and time of the treatment is
sufficient. Such indicators include, for example, clinically
recognized indicators of disease severity, symptoms, or
manifestations of the disorder in question. In most instances, an
improvement is considered to be sustained if the patient exhibits
the improvement on at least two occasions separated by two to four
weeks. The degree of improvement generally is determined by the
patient's physician, who may make this determination based on signs
or symptoms, and who may also employ questionnaires that are
administered to the patient, such as quality-of-life questionnaires
developed for a given disease.
[0222] As one example, in treating benign prostate hyperplasia, an
IL-4 inhibitor is administered to the patient in an amount and for
a time effective in scar regression or complete healing.
Maintenance doses may be given or treatment resumed as needed.
[0223] Elevated levels of IL-4 are associated with a number of
disorders, as discussed above. Patients with a given disorder may
be screened, to identify those individuals who have elevated IL-4
levels, or to identify those with an elevated TH2-type immune
response, thereby identifying the patients who may benefit most
from treatment with an IL-4 antagonist. Thus, treatment methods
provided herein optionally comprise a first step of measuring a
patient's IL-4 level. An IL-4 antagonist may be administered to a
patient in whom IL-4 levels are elevated above normal.
Alternatively or additionally, a patient may be pre-screened to
determine whether the patient has an elevated TH2-type immune
response, prior to administration of antagonist(s) against one or
more TH2-type cytokines.
[0224] A patient's levels of IL-4 (and, optionally, of other
TH2-type cytokines) may be monitored during and/or after treatment
with an IL-4 antagonist, to detect reduction in the levels of the
cytokines. For some disorders, the incidence of elevated IL-4
levels, and the balance between TH1-type and TH2-type immune
responses, may vary according to such factors as the stage of the
disease or the particular form of the disease. Known techniques may
be employed for measuring IL-4 levels, e.g., in a patient's serum,
and for assessing TH2-type immune responses. Cytokine levels in
blood samples may be measured by ELISA, for example.
[0225] Particular embodiments of methods and compositions of the
invention involve the use of two or more different IL-4
antagonists. In further embodiments, IL-4 antagonist(s) are
administered alone or in combination with other agents useful for
treating the condition with which the patient is afflicted.
Examples of such agents include both proteinaceous and
non-proteinaceous drugs. When multiple therapeutics are
co-administered, dosages may be adjusted accordingly, as is
recognized in the pertinent art. "Co-administration" and
combination therapy are not limited to simultaneous administration,
but include treatment regimens in which an IL-4 antagonist is
administered at least once during a course of treatment that
involves administering at least one other therapeutic agent to the
patient.
[0226] Examples of other agents that may be co-administered with
IL-4 antagonists are other antibodies, cytokines, or cytokine
receptors, which are chosen according to the particular condition
to be treated. Alternatively, non-proteinaceous drugs that are
useful in treating one of the particular conditions discussed above
may be co-administered with an IL-4 antagonist.
[0227] For treating IgE-mediated conditions, an IL-4 antagonist may
be co-administered with an IgE antagonist. One example is an
anti-IgE antibody. Humanized anti-IgE monoclonal antibodies are
described in Presta et al. (J. Immunol. 151(5):2623-2632, 1993) and
Adelroth et al. (J. Allergy Clin. Immunol. 106(2):253-259, 2000),
for example.
[0228] IL-4 antagonists may be co-administered with an IL-5
antagonist, which may be a molecule that interferes with the
binding of IL-5 to an IL-5 receptor, such as an anti-IL-5 antibody
(e.g., a human or humanized anti-IL-5 monoclonal antibody), or a
receptor such as a soluble human IL-5 receptor polypeptide. IL-5
has been implicated as playing a role in mediating allergic
responses. Thus, administration of antagonist(s) of IL-4 and IL-5
is contemplated for treatment of allergic reactions, including but
not limited to allergic asthma.
[0229] IL-4 antagonists may be employed in conjunction with other
agent(s) in treating the particular IL-4-induced conditions
discussed above. For example, drugs currently employed in treating
the conditions may be co-administered with one or more IL-4
antagonists.
[0230] For treating asthma, an IL-4 antagonist may be
co-administered with other anti-asthma medications, such as inhaled
corticosteroids, beta agonists, leukotriene antagonists, xanthines,
fluticasone, salmeterol, albuterol, non-steroidal agents such as
cromolyn, and the like. IL-4 antagonists may be co-administered
with other anti-allergy medications to treat allergic
reactions.
[0231] One embodiment of the present invention is directed to
co-administration of an IL-4 antagonist (such as a soluble human
IL-4R) and fluticasone and salmeterol to treat a disorder such as
asthma. Compositions comprising an IL-4 inhibitor (e.g., soluble
human IL-4R), fluticasone, and salmeterol are provided herein.
Advair Diskus (Glaxo Wellcome) comprises fluticasone propionate and
salmeterol xinafoate. For treating asthma, Advair Diskus and the
IL-4 antagonist preferably are delivered by inhalation.
[0232] Another example of combination therapy comprises
co-administration of an IL-4 antagonist and an IL-9 antagonist to a
patient who has asthma. Any suitable IL-9 antagonist may be
employed, such as an IL-9 receptor (preferably a soluble form
thereof), an antibody that interferes with binding of IL-9 to a
cell surface receptor (wherein the antibody may be raised against
IL-9 or an IL-9 receptor polypeptide), or another compound that
inhibits IL-9-induced biological activity. IL-9 receptors include
those described in WO 93/18047 and U.S. Pat. Nos. 5,789,237 and
5,962,269, which are hereby incorporated by reference herein.
[0233] In an additional embodiment of combination therapy, a method
for treating ulcerative colitis comprises co-administration of at
least one IL-4 antagonist and at least one IL-1 antagonist.
Examples of IL-1 antagonists include type I IL-1 receptor, type II
IL-1 receptor, IL-1 receptor antagonist (IL-1Ra), antagonistic
(blocking) antibodies directed against IL-1, and antagonistic
antibodies directed against an IL-1 receptor. Various forms of the
receptors may be employed, such as fragments, variants and fusions
analogous to those described above for IL-4 receptor. A preferred
IL-1 antagonist is a soluble form of type II IL-1 receptor, which
is described in U.S. Pat. No. 5,350,683, hereby incorporated by
reference herein.
[0234] One method of the present invention comprises
co-administering IL-4 antagonist(s) and IL-13 antagonist(s) to a
patient who has minimal change nephrosis. Alternative embodiments
involve administering IL-4 antagonist(s) alone, or IL-13
antagonist(s) alone, to a minimal change nephrosis patient. The
IL-4 antagonists(s) and/or IL-13 antagonist(s) may be administered
to reduce severity of the disease.
[0235] Another method provided herein is a method for treating
various allergic inflammatory conditions, comprising
co-administering IL-4 antagonist(s) and IL-13 antagonist(s).
Conditions such as asthma, allergies, and chronic lung diseases
such as cystic fibrosis and chronic obstructive pulmonary disease
are treated by such a method.
[0236] Any suitable IL-13 antagonist may be employed, including but
not limited to IL-13 receptors (preferably soluble forms thereof),
IL-13 receptor antagonists, antibodies directed against IL-13 or an
IL-13 receptor, other proteins that interfere with the binding of
IL-13 to an IL-13 receptor, and compounds that inhibit
IL-13-mediated signal transduction. IL-13 receptors and
heterodimers comprising IL-13R polypeptides as components thereof
are described above. Antibodies that are raised against IL-4R may
be screened for the ability to also function as IL-13 antagonists,
as discussed above.
[0237] A method for treating or preventing a condition
characterized by reduced epithelial barrier function comprises
co-administering IL-4 antagonist(s) and one or more IL-13
antagonists. Such conditions are discussed above. In one
embodiment, the condition is asthma. Particular embodiments are
directed to co-administering one or more IL-4 antagonists and one
or more IL-13 antagonists to a patient having a condition involving
reduction of lung epithelial barrier function or intestinal
epithelial barrier function, wherein both IL-4 and IL-13 play a
role in the reduced barrier function. The method thus inhibits both
IL-4-induced reduction of barrier function and IL-13-induced
reduction of barrier function. The adverse effect of IL-13 on lung
and intestinal epithelial barrier function can be confirmed using
assay techniques such as those described in example 7 below. (See
also Zund et al., J. Biol. Chem. 271(13):7460-7464, 1996.)
[0238] Another method provided herein comprises co-administering
IL-4 antagonist(s) and interferon-.gamma. (IFN-.gamma.) to a
patient having a condition involving reduction of lung epithelial
barrier function. Optionally, such a method further comprises
co-administering one or more IL-13 antagonists to the patient
(i.e., co-administering an IL-4 antagonist, IFN-.gamma., and an
IL-13 antagonist). Other methods comprise administering IFN-.gamma.
as a single agent, or co-administering IFN-.gamma. and an IL-13
antagonist, to a patient having a condition involving reduction of
lung epithelial barrier function. In one embodiment, the patient
has asthma. For treating asthma, the IL-4 antagonist, IFN-.gamma.,
and/or IL-13 antagonist preferably are administered by
inhalation.
[0239] One method provided herein for treating asthma comprises
administering an IL-4 antagonist and interferon-.gamma. to a human
who has asthma. Another method for treating asthma comprises
co-administering an IL-4 antagonist, IFN-.gamma., and an IL-13
antagonist to a human who has asthma. In one embodiment,
IFN-.gamma. is co-administered to an asthmatic, together with an
antibody that functions as an antagonist of both IL-4 and IL-13.
Such antibodies are described elsewhere herein.
[0240] A single agent may function as an IL-4 antagonist and an
IL-13 antagonist, as discussed above. As an example of such an
agent, some antibodies raised against IL-4R.alpha. may interfere
with the binding of both IL-4 and IL-13 receptor complexes, due to
the shared IL-4R.alpha. component in such multi-subunit receptor
complexes (discussed above). Thus, a single agent may be employed
in a method for inhibiting reduction of barrier function.
[0241] Antagonists may be co-administered with one or more
leukotriene receptor antagonists to treat disorders such as
allergic inflammatory diseases, e.g., asthma and allergies.
Examples of leukotriene receptor antagonists include but are not
limited to montelukast, pranlukast, and zafirlukast. Drugs that
function as 5-lipoxygenase inhibitors may be co-administered with
an IL-4 antagonist to treat asthma.
[0242] Methods provided herein comprise administering one or more
of the following to Churg-Strauss Syndrome patients: IL-4
antagonist(s), IL-5 antagonist(s), IL-13 antagonist(s) or IgE
antagonist(s). One example of such a method involves
co-administering IL-4 antagonist(s) and IL-5 antagonist(s) to a
Churg-Strauss Syndrome patient. In another embodiment, IL-4
antagonist(s) and IgE antagonist(s) are co-administered to the
patient. In yet another embodiment, IL-4 antagonist(s) and IL-13
antagonist(s) are co-administered to the patient.
[0243] The hormone relaxin may be co-administered with an IL-4
antagonist to treat scleroderma (systemic sclerosis), idiopathic
pulmonary fibrosis, or any other disorder characterized by
pulmonary fibrosis, such as the conditions involving fibrosis of
the lung that are discussed above. Recombinant human relaxin is
preferred for use in treating humans.
[0244] A method for treating benign prostate hyperplasia comprises
co-administering IL-4 antagonist(s) and one or more additional
anti-inflammatory agents. Examples of agents that inhibit
inflammation include tumor necrosis factor (TNF) antagonists and
IL-17 antagonists.
[0245] Any suitable IL-17 antagonist may be employed, including but
not limited to an IL-17 receptor (preferably soluble forms
thereof), IL-17 receptor antagonists, antibodies directed against
IL-17 or an IL-17 receptor, other proteins that interfere with the
binding of IL-17 to an IL-17 receptor, and compounds that inhibit
IL-17-mediated signal transduction. An IL-17 receptor, including
soluble forms thereof and oligomers thereof, is described in WO
96/29408, hereby incorporated by reference. An alternative method
provided herein comprises administering an IL-17 antagonist to
treat a patient with benign prostate hyperplasia.
[0246] Likewise, any suitable TNF antagonist may be employed,
including but not limited to a TNF receptor (preferably soluble
forms thereof), fusion proteins comprising a TNF receptor (or
comprising the TNF-binding portion of a TNF receptor), TNF receptor
antagonists, antibodies directed against TNF or a TNF receptor,
other proteins that interfere with the binding of TNF to a TNF
receptor, and compounds that inhibit TNF-mediated signal
transduction. Further examples of TNF inhibitors are the drugs
thalidomide and pentoxyfylline. The TNF receptor protein known as
p75 or p80 TNF-R preferably is employed. A preferred TNF antagonist
is a soluble human TNF receptor (sTNF-R) in dimeric form, such as
dimers of sTNF-R/Fc fusion proteins. One such dimer is etanercept
(Enbrel.RTM., Immunex Corporation, Seattle, Wash.). p75/p80 TNF-R,
including soluble fragments and other forms thereof, is described
in WO 91/03553, hereby incorporated by reference herein.
[0247] In accordance with the present invention, an IL-4 antagonist
is co-administered with a TNF antagonist to treat any condition in
which undesirable IL-4-induced and TNF-induced immune responses
play a role, such as inflammation. One method provided herein
comprises co-administering an IL-4 antagonist and a TNF antagonist
to a patient with inflammatory bowel disease, Crohn's disease, or
ulcerative colitis. Other embodiments are directed to a method
comprising co-administering an IL-4 antagonist and a TNF antagonist
to a patient who has Kawasaki Disease, autoimmune hemolytic anemia,
autoimmune uveoretinitis, autoimmune lymphoproliferative syndrome,
Sjogren's syndrome, chronic fatigue syndrome, or hepatotoxicity
induced by a drug such as diclofenac.
[0248] Another method provided herein comprises co-administering an
IL-4 antagonist and a TNF antagonist to a pregnant woman who has
developed pre-eclampsia. Administration of the IL-4 antagonist and
TNF-antagonist preferably continues for the duration of the
pregnancy.
[0249] Suitable dosages of etanercept (Enbrel.RTM., Immunex
Corporation, Seattle, Wash.) will vary according to the nature of
the disease to be treated, disease severity, the size of the
patient (e.g., adult or child), and other factors, as is recognized
in the pertinent field. In one embodiment of the methods provided
herein, Enbrel.RTM. is administered twice a week by subcutaneous
injection at a dose of from 1 to 25 mg. One embodiment of a
pediatric dosage is 0.4 mg/kg. Particular methods provided herein
comprise co-administration of an IL-4 antagonist and Enbrel.RTM. to
a patient has autoimmune lymphoproliferative syndrome or Sjogren's
syndrome, wherein Enbrel.RTM. is given by subcutaneous injection at
a dose of from 1 to 25 mg.
[0250] For treating graft versus host disease, an IL-4 antagonist
is co-administered with at least one of the following agents: a TNF
antagonist, an IL-1 antagonist, steroids, or corticosteroids. The
TNF inhibitor preferably is Enbrel.RTM.. A preferred IL-1
antagonist is a soluble form of type II IL-1 receptor, which is
described in U.S. Pat. No. 5,350,683. In one embodiment, the GVHD
is associated with (e.g., develops subsequent to) bone marrow
transplantation. An IL-4 antagonist may be employed in combination
with at least one of the above-listed agents, in methods for
suppressing an immune response directed against transplanted cells,
tissue, and/or alloantigen.
[0251] A number of cytokine antagonists and other agents/drugs are
disclosed herein as being useful for combination therapy (e.g.,
co-administration with an IL-4 antagonist) in treating particular
diseases. It is to be understood that such antagonists, agents, or
drugs also find use as single agents in treating those diseases. It
also is to be understood that disclosure of methods involving
administration of an antagonist to a particular cytokine, to treat
a disease, encompasses administration of one type of antagonist,
and also encompasses administration of two or more different
antagonists for that cytokine, unless specified otherwise.
[0252] The following examples are offered by way of illustration,
and not by way of limitation.
Example 1: Preparation of Monoclonal Antibodies
[0253] IL-4 receptor polypeptides may be employed as immunogens in
generating monoclonal antibodies by conventional techniques, e.g.,
techniques described in U.S. Pat. No. 5,599,905, hereby
incorporated by reference. It is recognized that polypeptides in
various forms may be employed as immunogens, e.g., full length
proteins, fragments thereof, fusion proteins thereof such as Fc
fusions, cells expressing the recombinant protein on the cell
surface, etc.
[0254] To summarize an example of such a procedure, an IL-4R
immunogen emulsified in complete Freund's adjuvant is injected
subcutaneously into Lewis rats, in amounts ranging from 10-100
.mu.l. Three weeks later, the immunized animals are boosted with
additional immunogen emulsified in incomplete Freund's adjuvant and
boosted every three weeks thereafter. Serum samples are
periodically taken by retro-orbital bleeding or tail-tip excision
for testing by dot-blot assay, ELISA (enzyme-linked immunosorbent
assay), or inhibition of binding of .sup.125I-IL-4 to extracts of
IL-4R-expressing cells. Following detection of an appropriate
antibody titer, positive animals were given a final intravenous
injection of antigen in saline. Three to four days later, the
animals are sacrificed, splenocytes harvested, and fused to the
murine myeloma cell line AG8653. The resulting hybridoma cell lines
are plated in multiple microtiter plates in a HAT selective medium
(hypoxanthine, aminopterin, and thymidine) to inhibit proliferation
of non-fused cells, myeloma hybrids, and spleen cell hybrids.
[0255] Hybridoma clones thus generated are screened for reactivity
with IL-4R. Initial screening of hybridoma supernatants utilizes an
antibody capture and binding of partially purified .sup.125I-IL-4
receptor. Hybridomas that are positive in this screening method are
tested by a modified antibody capture to detect hybridoma cells
lines that are producing blocking antibody. Hybridomas that secrete
a monoclonal antibody capable of inhibiting .sup.125I-IL-4 binding
to cells expressing IL-4R are thus detected. Such hydridomas then
are injected into the peritoneal cavities of nude mice to produce
ascites containing high concentrations (>1 mg/ml) of anti-IL-4R
monoclonal antibody. The resulting monoclonal antibodies may be
purified by ammonium sulfate precipitation followed by gel
exclusion chromatography, and/or affinity chromatography based on
binding of antibody to Protein G.
Example 2: Generation of Cmu Targeted Mice
[0256] This example describes procedures for generating transgenic
mice. Additional procedures for generating transgenic mice, and the
use of such mice for preparing human antibodies, are described in
Examples 3 and 4.
[0257] Construction of a CMD Targeting Vector.
[0258] The plasmid pICEmu contains an EcoRI/XhoI fragment of the
murine Ig heavy chain locus, spanning the mu gene, that was
obtained from a Balb/C genomic lambda phage library (Marcu et al.
Cell 22: 187, 1980). This genomic fragment was subcloned into the
XhoI/EcoRI sites of the plasmid pICEMI9H (Marsh et al; Gene 32,
481-485, 1984). The heavy chain sequences included in pICEmu extend
downstream of the EcoRI site located just 3' of the mu intronic
enhancer, to the XhoI site located approximately 1 kb downstream of
the last transmembrane exon of the mu gene; however, much of the mu
switch repeat region has been deleted by passage in E. coli.
[0259] The targeting vector was constructed as follows. (See FIGS.
2A-2C, which depict further details.) A 1.3 kb HindIII/SmaI
fragment was excised from pICEmu and subcloned into HindIII/SmaI
digested pBluescript (Stratagene, La Jolla, Calif.). This pICEmu
fragment extends from the HindIII site located approximately 1 kb
5' of Cmu1 to the SmaI site located within Cmu1. The resulting
plasmid was digested with SmaI/SpeI and the approximately 4 kb
SmaI/XbaI fragment from pICEmu, extending from the Sma I site in
Cmu1 3' to the XbaI site located just downstream of the last Cmu
exon, was inserted. The resulting plasmid, pTAR1, was linearized at
the SmaI site, and a neo expression cassette inserted. This
cassette consists of the neo gene under the transcriptional control
of the mouse phosphoglycerate kinase (pgk) promoter (XbaI/TaqI
fragment; Adra et al. (1987) Gene 60: 65-74) and containing the pgk
polyadenylation site (PvuII/HindIII fragment; Boer et al. (1990)
Biochemical Genetics 28: 299-308). This cassette was obtained from
the plasmid pKJ1 (described by Tybulewicz et al. (1991) Cell 65:
1153-1163) from which the neo cassette was excised as an
EcoRI/HindIII fragment and subcloned into EcoRI/HindIII digested
pGEM-7Zf (+) to generate pGEM-7 (KJ1). The neo cassette was excised
from pGEM-7 (KJ1) by EcoRI/SalI digestion, blunt ended and
subcloned into the SmaI site of the plasmid pTAR1, in the opposite
orientation of the genomic Cmu sequences.
[0260] The resulting plasmid was linearized with Not I, and a
herpes simplex virus thymidine kinase (tk) cassette was inserted to
allow for enrichment of ES clones bearing homologous recombinants,
as described by Mansour et al. (1988) Nature 336: 348-352. This
cassette consists of the coding sequences of the tk gene bracketed
by the mouse pgk promoter and polyadenylation site, as described by
Tybulewicz et al. (1991) Cell 65:1153-1163.
[0261] The resulting CMD targeting vector contains a total of
approximately 5.3 kb of homology to the heavy chain locus and is
designed to generate a mutant mu gene into which has been inserted
a neo expression cassette in the unique SmaI site of the first Cmu
exon. The targeting vector was linearized with PvuI, which cuts
within plasmid sequences, prior to electroporation into ES
cells.
[0262] Generation and Analysis of Targeted ES Cells.
[0263] AB-1 ES cells (McMahon, A. P. and Bradley, A., (1990) Cell
62: 1073-1085) were grown on mitotically inactive SNL76/7 cell
feeder layers (ibid.), essentially as described in Teratocarcinomas
and Embryonic Stem Cells: a Practical Approach, E. J. Robertson,
Ed., Oxford: IRL Press, 1987, pp. 71-112. The linearized CMD
targeting vector was electroporated into AB-1 cells by the methods
described in Hasty et al. (1991) Nature 350: 243-246.
Electroporated cells were plated into 100 mm dishes at a density of
1-2.times.10.sup.6 cells/dish. After 24 hours, G418 (200
micrograms/ml of active component) and FIAU (5.times.10.sup.-7 M)
were added to the medium, and drug-resistant clones were allowed to
develop over 8-9 days. Clones were picked, trypsinized, divided
into two portions, and further expanded. Half of the cells derived
from each clone were then frozen and the other half analyzed for
homologous recombination between vector and target sequences.
[0264] DNA analysis was carried out by Southern blot hybridization.
DNA was isolated from the clones as described by Laird et al.,
(1991) Nucleic Acids Res. 19:4293). Isolated genomic DNA was
digested with SpeI and probed with a 915 bp SacI fragment, probe A
(FIG. 2C), which hybridizes to a sequence between the mu intronic
enhancer and the mu switch region. Probe A detects a 9.9 kb SpeI
fragment from the wild type locus, and a diagnostic 7.6 kb band
from a mu locus which has homologously recombined with the CMD
targeting vector (the neo expression cassette contains a SpeI
site).
[0265] Of 1132 G418 and FIAU resistant clones screened by Southern
blot analysis, 3 displayed the 7.6 kb Spe I band indicative of
homologous recombination at the mu locus. These 3 clones were
further digested with the enzymes BglI, BstXI, and EcoRI to verify
that the vector integrated homologously into the mu gene. When
hybridized with probe A, Southern blots of wild type DNA digested
with BglI, BstXI, or EcoRI produce fragments of 15.7, 7.3, and 12.5
kb, respectively, whereas the presence of a targeted mu allele is
indicated by fragments of 7.7, 6.6, and 14.3 kb, respectively. All
3 positive clones detected by the SpeI digest showed the expected
BglI, BstXI, and EcoRI restriction fragments diagnostic of
insertion of the neo cassette into the Cmu1 exon.
[0266] Generation of Mice Bearing the Mutated Mu Gene.
[0267] The three targeted ES clones, designated number 264, 272,
and 408, were thawed and injected into C57BL/6J blastocysts as
described by A. Bradley in Teratocarcinomas and Embryonic Stem
Cells: a Practical Approach, E. J. Robertson, Ed., Oxford: IRL
Press, 1987, pp. 113-151. Injected blastocysts were transferred
into the uteri of pseudopregnant females to generate chimeric mice
representing a mixture of cells derived from the input ES cells and
the host blastocyst. The extent of ES cell contribution to the
chimera can be visually estimated by the amount of agouti coat
coloration, derived from the ES cell line, on the black C57BL/6J
background. Clones 272 and 408 produced only low percentage
chimeras (i.e. low percentage of agouti pigmentation) but clone 264
produced high percentage male chimeras. These chimeras were bred
with C57BL/6J females and agouti offspring were generated,
indicative of germline transmission of the ES cell genome.
Screening for the targeted mu gene was carried out by Southern blot
analysis of BglI digested DNA from tail biopsies (as described
above for analysis of ES cell DNA). Approximately 50% of the agouti
offspring showed a hybridizing BglI band of 7.7 kb in addition to
the wild type band of 15.7 kb, demonstrating a germline
transmission of the targeted mu gene.
[0268] Analysis of Transgenic Mice for Functional Inactivation of
Mu Gene.
[0269] To determine whether the insertion of the neo cassette into
Cmu1 has inactivated the Ig heavy chain gene, a clone 264 chimera
was bred with a mouse homozygous for the JHD mutation, which
inactivates heavy chain expression as a result of deletion of the
JH gene segments (Chen et al, (1993) Immunol. 5: 647-656). Four
agouti offspring were generated. Serum was obtained from these
animals at the age of 1 month and assayed by ELISA for the presence
of murine IgM. Two of the four offspring were completely lacking
IgM (Table 1). Genotyping of the four animals by Southern blot
analysis of DNA from tail biopsies by BglI digestion and
hybridization with probe A (FIG. 2C), and by StuI digestion and
hybridization with a 475 bp EcoRI/StuI fragment (ibid.)
demonstrated that the animals which fail to express serum IgM are
those in which one allele of the heavy chain locus carries the JHD
mutation, the other allele the Cmu1 mutation. Mice heterozygous for
the JHD mutation display wild type levels of serum Ig. These data
demonstrate that the Cmu1 mutation inactivates expression of the mu
gene.
[0270] Table 1 presents the level of serum IgM, detected by ELISA,
for mice carrying both the CMD and JHD mutations (CMD/JHD), for
mice heterozygous for the JHD mutation (+/JHD), for wild type
(129Sv.times.C57BL/6J)F1 mice (+/+), and for B cell deficient mice
homozygous for the JHD mutation (JHD/JHD).
TABLE-US-00001 TABLE 1 Mouse Serum IgM (micrograms/ml) Ig H chain
genotype 42 <0.002 CMD/JHD 43 196 +/JHD 44 <0.002 CMD/JHD 45
174 +/JHD 129 .times. BL6 F1 153 +/+ JHD <0.002 JHD/JHD
Example 3: Generation of Transgenic Mice
[0271] The HCo12 Human Heavy Chain Transgene.
[0272] The HCo12 transgene was generated by coinjection of the 80
kb insert of pHC2 (Taylor et al., 1994, Int. Immunol., 6: 579-591)
and the 25 kb insert of pVx6. The plasmid pVx6 was constructed as
described below.
[0273] An 8.5 kb HindIII/SalI DNA fragment, comprising the germline
human VH1-18 (DP-14) gene together with approximately 2.5 kb of 5'
flanking, and 5 kb of 3' flanking genomic sequence was subcloned
into the plasmid vector pSP72 (Promega, Madison, Wis.) to generate
the plasmid p343.7.16. A 7 kb BamHI/HindIII DNA fragment,
comprising the germline human VH5-51 (DP-73) gene together with
approximately 5 kb of 5' flanking and 1 kb of 3' flanking genomic
sequence, was cloned into the pBR322 based plasmid cloning vector
pGP1f (Taylor et al. 1992, Nucleic Acids Res. 20: 6287-6295), to
generate the plasmid p251f.
[0274] A new cloning vector derived from pGP1f, pGP1k (the sequence
of which is presented in FIGS. 3A and 3B and SEQ ID NO:4), was
digested with EcoRV/BamHI, and ligated to a 10 kb EcoRV/BamHI DNA
fragment, comprising the germline human VH3-23 (DP47) gene together
with approximately 4 kb of 5' flanking and 5 kb of 3' flanking
genomic sequence. The resulting plasmid, p112.2RR.7, was digested
with BamHI/SalI and ligated with the 7 kb purified BamHI/SalI
insert of p251f. The resulting plasmid, pVx4, was digested with
XhoI and ligated with the 8.5 kb XhoI/SalI insert of p343.7.16. A
clone was obtained with the VH1-18 gene in the same orientation as
the other two V genes. This clone, designated pVx6, was then
digested with NotI and the purified 26 kb insert coinjected,
together with the purified 80 kb NotI insert of pHC2 at a 1:1 molar
ratio, into the pronuclei of one-half day (C57BL/6J.times.DBA/2J)F2
embryos as described by Hogan et al. (B. Hogan et al., Manipulating
the Mouse Embryo, A Laboratory Manual, 2.sup.nd edition, 1994, Cold
Spring Harbor Laboratory Press, Plainview N.Y.).
[0275] Three independent lines of transgenic mice comprising
sequences from both Vx6 and HC2 were established from mice that
developed from the injected embryos. These lines are designated
(HCo12)14881, (HCo12)15083, and (HCo12)15087. Each of the three
lines were then bred with mice comprising the CMD mutation
described in Example 2, the JKD mutation (Chen et al. 1993, EMBO J.
12: 811-820), and the (KCo5)9272 transgene (Fishwild et al. 1996,
Nature Biotechnology 14: 845-851). The resulting mice express human
heavy and kappa light chain transgenes in a background homozygous
for disruption of the endogenous mouse heavy and kappa light chain
loci.
[0276] Additional Transgenic Mouse Strains
[0277] Particular strains of mice that may be used to generate
IL-4R-reactive monoclonal antibodies are strain ((CMD)++; (JKD)++;
(HCo7) 11952+/++; (KCo5)9272+/++), and strain ((CMD)++; (JKD)++;
(HCo12)15087+/++; (KCo5)9272+/++). Each of these transgenic strains
is homozygous for disruptions of the endogenous heavy chain (CMD)
and kappa light chain (JKD) loci. Both strains also comprise a
human kappa light chain transgene (HCo7), with individual animals
either hemizygous or homozygous for insertion #11952. The two
strains differ in the human heavy chain transgene used. Mice were
hemizygous or homozygous for either the HCo7 or the HCo12
transgene. The CMD mutation is described above in Example 2. The
generation of (HCo12)15087 mice is described above (in this
example). The JKD mutation (Chen et al. 1993, EMBO J. 12: 811-820)
and the (KCo5)9272 (Fishwild et al. 1996, Nature Biotechnology 14:
845-851) and (HCo7)11952 mice, are described in U.S. Pat. No.
5,770,429, which is hereby incorporated by reference.
Example 4: Generation of Human Anti-IL-4R Monoclonal Antibodies
[0278] Transgenic Mice
[0279] Strain ((CMD)++; (JKD)++; (HCo7)11952+/++; (KCo5)9272+/++
which is homozygous for disruptions of the endogenous heavy chain
(CMD) and kappa light chain (JKD) loci (see example 3), was used to
generate IL-4R-reactive monoclonal antibodies. This strain also
comprises a human kappa light chain transgene (HCo7) with
individual animals either hemizygous or homozygous for insertion
#11952. Mice were hemizygous or homozygous for the HCo7 transgene.
The CMD mutation is described above in Example 2. The JKD mutation
(Chen et al. 1993, EMBO J. 12: 811-820) and the (KCo5)9272
(Fishwild et al. 1996, Nature Biotechnology 14: 845-851) and
(HCo7)11952 mice, are described in U.S. Pat. No. 5,770,429, which
is hereby incorporated by reference.
[0280] Immunization.
[0281] Transgenic mice were initially immunized i.p. with 25 ug
IL-4R protein in adjuvant (Titermax, available from Cytrx
Corporation, Norcross, Ga.). The immunogen was a human IL-4R
polypeptide comprising the extracellular domain of the protein of
SEQ ID NO:2. Immunized mice were subsequently boosted every 4 weeks
i.p. with the IL-4R immunogen in incomplete freunds adjuvant.
Animals were kept on protocol for 2 to 5 months. Prior to fusion,
animals were boosted i.v. on days -4 and -3 with 5 to 8 ug
immunogen.
[0282] Fusions.
[0283] Spleen cells harvested from the immunized mice were fused to
mouse myeloma cells NS-1 by standard procedures (Harlow and Lane,
1988, Antibodies, A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor N.Y.; Kennett et al. 1980,
Monoclonal Antibodies, Hybridomas: A New Dimension in Biological
Analysis. Plenum, N.Y.; Oi and Hertzenberg, 1980, Immunoglobulin
Producing Hybrid Cell Lines, in Selected Methods In Cellular
Immunology, ed. Mishell and Shiigi, pp. 357-372. Freeman, San
Francisco). Cells were cultured in DMEM, 10% FBS, OPI (Sigma
0-5003), BME (Gibco 21985-023), 3% Origen Hybridoma Cloning Factor
(Igen IG50-0615), and 5% P388d1 (ATCC TIB 63) conditioned media.
HAT or HT supplement was added to the medium during initial growth
and selection.
[0284] Hybridoma Screening.
[0285] To identify hybridomas secreting human antibodies against
the IL-4R, ELISA plates (Nunc MaxiSorp) were coated overnight at
4.degree. C. with 100 ul/well human IL-4R at 2.0 ug/ml in PBS.
Plates were washed with 100 ul/well PBS-Tween (PBST) containing 1%
BSA. Fifty ul cell culture supernatent was added followed by a 1.0
hour incubation. Plates were washed and then incubated for one hour
with 100 ul/well goat anti-human IgG conjugated to horseradish
peroxidase (Sigma #A-3813, or #A-7164). Plates were washed three
times in PBS-Tween between each step.
[0286] Wells that read positive by ELISA were screened for their
ability to block the binding of IL-4 to IL-4R. ELISA plates were
coated overnight with a non-neutralizing mouse anti-human IL-4R
antibody M10 at 2 ug/ml. Plates were washed 3.times. with PBST. 100
ul human IL-4R was added at 10 ng/ml in PBST and incubated for 1.0
hour. Plates were washed 4.times. with PBST and 100 ul supernatant
samples were added and incubated for 1.0 hour. Wells were washed
4.times. with PBST. 5.0 ng/ml biotinylated IL-4 was added in PBST
and incubated for 1.0 hour. 100 ul/well poly80 horseradish
peroxidase (RDI) was added at 1:5000 in PBST and incubated for 45
minutes. Plates were washed 5.times. with PBST, and a colorimetric
reagent (3,3',5,5' tetramethylbenzidine, available from Kirkegaard
and Perry) was added at 100 ul/well until color developed. Reaction
was stopped with 100 ul phosphoric acid and plates were read at 450
nm. Absent or reduced signal was interpreted as the antibody
binding to receptor in a manner that blocked IL-4 from binding to
receptor. Wells that appeared to block binding were expanded and
tested for IL-4 and IL-13 blocking in a CD23 expression assay (see
example 5).
Example 5: Assay for Assessing Blocking Activity
[0287] This assay is based on ability of both IL-4 and IL-13 to
enhance the expression of the activation-associated surface antigen
CD23 on human B cells. Antibodies are tested for the ability to
inhibit CD23 expression induced by IL-4 and by IL-13.
[0288] Antibodies raised against human IL-4R (huIL-4R) were tested
either in the form of hybridoma supernatants or purified protein.
Prior to addition to cultures, the antibodies were buffer exchanged
against culture medium (RPMI 1640 plus 10% heat-inactivated fetal
bovine serum) by centrifugation, using Centricon filter devices
(Amicon) with a 10 kDa cutoff.
[0289] Human peripheral blood B cells were purified as described
previously (Morris et al., J. Biol. Chem. 274:418-423, 1999). The B
cells (3.times.10.sup.5/well) in culture medium were placed in
96-well round-bottomed microtiter plates and preincubated at room
temperature for 30 min with test antibodies at the final
concentrations indicated. Recombinant human IL-4 or IL-13 was then
added to the cultures at the concentrations indicated, and cells
were cultured for 20-24 hours at 37.degree. C. in a humidified
atmosphere of 5% CO.sub.2. At the end of the culture period, cells
were washed once in PBS+0.02% NaN.sub.3 in the 96-well culture
plate and were resuspended in blocking buffer (2% normal rabbit
serum+1% normal goat serum in PBS+NaN.sub.3). Phycoerythrin
(PE)-conjugated CD23 monoclonal antibody (mAb) or PE-conjugated
isotype control mAb (both from Pharmingen) was then added to cells
at a final dilution of 1:10. Cells were incubated for 30 minutes at
4.degree. C., washed .times.3 in PBS+NaN.sub.3 and analyzed on a
FacScan (Becton Dickinson) for CD23 expression.
[0290] In all experiments, negative controls were included which
consisted of cells cultured with hybridoma growth medium or
isotype-matched non-blocking human anti-hIL-4R antibody. An
anti-huIL-4R murine mAb (R&D Systems), previously shown to
block the binding and function of both hIL-4 and hIL-13, was used
as a positive control for neutralization of CD23 induction by IL-4
and IL-13.
Example 6: Hybridoma Cell Line
[0291] One hybridoma cell line generated by procedures described
above (see example 4) is designated 6-2. The anti-IL-4R monoclonal
antibody secreted by this hybridoma is a blocking antibody, as
determined in a conventional plate binding assay, and thus
functions as an IL-4 antagonist. The monoclonal antibody produced
by 6-2 also exhibits the ability to reduce an IL-13-induced
biological activity.
[0292] One embodiment of the invention is directed to a hybridoma
cell line produced as described above, wherein the hybridoma
secretes an isotype IgM MAb directed against human IL-4R. Also
provided herein are IgG1 monoclonal antibodies derived from IgM
monoclonal antibodies.
[0293] The DNA sequence of the variable region of the light chain
of MAb 6-2 has been determined, and is presented in SEQ ID NO:5;
the amino acid sequence encoded thereby is presented in SEQ ID
NO:6. Complementarity determining regions 1 to 3 (CDR 1-3) are
believed to correspond to amino acids 24-35, 51-57, and 90-97, of
SEQ ID NO:6, respectively.
[0294] The DNA sequence of the variable region of the heavy chain
of MAb 6-2 has been determined, and is presented in SEQ ID NO:7;
the amino acid sequence encoded thereby is presented in SEQ ID
NO:8. Complementarity determining regions 1 to 3 (CDR 1-3) are
believed to correspond to amino acids 31-35, 50-66, and 99-107 of
SEQ ID NO:8, respectively.
Example 7: Assays for Measuring Loss of Barrier Function
[0295] A method provided herein involves use of IL-4 antagonists to
inhibit IL-4-induced damage to epithelium, including but not
limited to lung epithelium or intestinal epithelium. Damage to
epithelium can result in loss of barrier function. A number of
techniques are known for determining whether an epithelial layer is
intact. The following are examples of techniques that may be
employed in assessing the ability of an IL-4 antagonist to inhibit
IL-4-induced damage to epithelium and loss of epithelial barrier
function.
[0296] Cells that may be employed in preparing in vitro models of
epithelium (epithelial barriers) are known. For example, Calu-3
human lung epithelial cells are suitable for use in barrier
function studies. Another suitable cell line is the human
intestinal epithelial cell line designated T84. T84 cells are
cultured under conditions that result in formation of a monolayer
of epithelial cells on a permeable support, as described in Madara,
J. and K. Dharmsathaphorn (J. Cell Biol., 101:2124-2133, 1985),
Madara, J. and J. Stafford (J. Clin. Invest. 83:724-727, 1989), and
Youakim, A. and M. Ahdieh (Am. J. Physiol. 276 (Gastrointest. Liver
Physiol. 39):G1279-G1288, 1999). The cultured monolayers are tested
for properties such as resistance to passive transepithelial ion
flow (such resistance indicating an intact monolayer performing a
barrier function). The thus-generated epithelial monolayer
simulates the intestinal epithelial barrier.
[0297] One type of assay determines whether a particular
radiolabeled compound is able to cross an epithelial monolayer
(e.g., a monolayer generated as described above). Transport of the
radiolabeled compound across the monolayer indicates that the
barrier is permeable rather than intact. One such procedure is
mannitol flux analysis, which assesses movement of radiolabeled
mannitol (e.g., .sup.3H mannitol) across a monolayer (see Madara
and Stafford, supra).
[0298] Methods for imaging a monolayer are identified in Madara and
Stafford, supra. Such imaging methods are an alternative for
assessing the condition of an epithelial layer, after exposure to
IL-4 with or without an antagonist.
[0299] Youakim and Ahdieh, supra, discuss proteins that are part of
"tight junction" complexes in intact intestinal epithelial
barriers, and report studies of the effect of IFN-.gamma. on
proteins associated with tight junctions. Other techniques for
studying the effect of a cytokine on barrier function are
described. For example, the effect of a cytokine on monolayer
permeability may be assessed by transepithelial electrical
resistance measurements, using techniques described in the
reference.
[0300] U.S. Pat. No. 6,033,688 also describes procedures that may
be employed in studies of barrier permeability; see especially
examples 1 and 4 of the patent. Human tracheal epithelial cells
were cultured under conditions that yielded a monolayer exhibiting
transepithelial electrical resistance. Transepithelial resistance
(indicating an intact barrier) was determined using a voltmeter.
The effect of a particular reagent (HGH) on the epithelial
monolayer was assessed by exposing the monolayer to HGH, and then
measuring ion transport activities in Ussing chambers, by standard
methods (column 8, lines 40-56). Similar studies were conducted on
monolayers that were generated from bronchial epithelial cells from
a human cystic fibrosis patient (example 4, column 11).
[0301] Using any of the above-described barrier function assay
procedures, an epithelial monolayer is exposed to IL-4 alone, or
exposed to IL-4 in the presence of an IL-4 antagonist. The
antagonist's ability to inhibit the IL-4-induced reduction in
barrier function thus is assessed.
[0302] In one such assay, a monolayer of T84 cells served as an in
vitro model of an intestinal epithelial barrier, as discussed
above. IL-4 added to the basolateral side of polarized epithelial
cells was found to reduce barrier function by 70% within 48-72
hours of treatment. When an IL-4 receptor polypeptide was added at
the same time as IL-4, the reduction in barrier function was
prevented, and the barrier was maintained at the same level as
untreated (control) cells. A soluble human IL-4 receptor
polypeptide, consisting of the extracellular domain, was employed
in the assay.
[0303] The assay procedure also was conducted on a monolayer
derived from lung epithelial cells, which served as an in vitro
model of a lung epithelial barrier. IL-4 added to the basolateral
side of polarized lung epithelial cells was found to reduce barrier
function by 50% within 48-72 hours of treatment. When the IL-4
receptor polypeptide was added at the same time as IL-4, the
reduction in barrier function was prevented, and the barrier was
maintained at the same level as untreated (control) cells.
Example 8: Monoclonal Antibody Designated 12B5
[0304] A human monoclonal antibody directed against human IL-4
receptor was prepared by the following procedure. The monoclonal
antibody, which is designated 12B5, is a blocking antibody that
functions as an IL-4 antagonist and as an IL-13 antagonist.
[0305] The procedure began with immunization of a transgenic mouse
with a soluble human IL-4 receptor polypeptide. Mouse strain
((CMD)++; (JKD)++; (HCo7)11952+/++; (KCo5)9272+/++), described in
example 3 above, was employed. The antigen for immunization was
purified soluble IL-4R, comprising the extracellular domain of
human IL-4 receptor (500 ug/ml). The mouse was initially immunized
with 50 ug antigen emulsified in Complete Freund's Adjuvant,
followed by two more immunizations with Incomplete Freund's
Adjuvant at 50 ug and then 25 ug. Immunization was every two weeks
by intraperitoneal injection. A specific human IgG anti-IL-4R titer
from the serum was performed by ELISA, eight days after the last
injection. A good titer against the target was detected, and the
mouse then was IV/IP boosted 25 ug each on day .sup.-3 (i.e., 3
days before the mouse was sacrificed) and 15 ug IV on day
.sup.-2.
[0306] The mouse was sacrificed, and spleen cells were extracted
and fused with the murine myeloma cell line P3x63Ag8.653 (ATCC CRL
1580). A conventional PEG fusion protocol was followed. The fusion
was screened for HuIgG and HuKappa, followed by a rescreen for
human gamma and kappa specific to IL-4R. The positive clones were
evaluated, and clone 12B5 was identified as a blocking antibody.
The clone was subcloned; a hybridoma cell line that produces MAb
12B5 was isolated; and MAb 12B5 was purified from the
supernatant.
[0307] 12B5 was determined to be an IgG1 antibody, and to be fully
human. Antibodies of other subclasses, such as IgG4 or IgM
monoclonal antibodies, may be derived from 12B5. Techniques for
altering (switching) the subclass/isotype of an antibody are known.
The constant region of 12B5 may be replaced, for example, with a
constant region derived from a human IgG4 antibody. Sequence
information for a human IgG4 heavy chain is presented, for example,
in Ellison et al. (DNA Vol. 1, no. 1, pp 11-18, 1981), which is
hereby incorporated by reference herein.
[0308] DNA encoding the variable region of the light chain of MAb
12B5 was isolated, and the nucleotide sequence thereof was
determined. The DNA sequence for the light chain variable region is
presented as SEQ ID NO:9; the amino acid sequence encoded thereby
is presented in SEQ ID NO:10. Complementarity determining regions 1
to 3 (CDR 1-3) are believed to correspond to amino acids 24-35,
51-57, and 90-99, of SEQ ID NO:10, respectively.
[0309] DNA encoding the variable region of the heavy chain of MAb
12B5 was isolated, and the nucleotide sequence thereof was
determined. The DNA sequence for the heavy chain variable region is
presented as SEQ ID NO:11; the amino acid sequence encoded thereby
is presented in SEQ ID NO:12. CDR-1 of the heavy chain is believed
to correspond to amino acids 31-35; CDR-2 to amino acids 50-65; and
CDR-3 to amino acids 98-104 of SEQ ID NO:12.
Example 9: Additional Monoclonal Antibodies that Inhibit Both IL-4
and IL-13
[0310] Additional human monoclonal antibodies were raised against
human IL-4 receptor, by immunizing transgenic mice with a soluble
human IL-4R polypeptide. The transgenic mice employed were selected
from the transgenic mouse strains described in example 3.
[0311] Hybridoma cell lines secreting human monoclonal antibodies
that specifically bind human IL-4R, and which are capable of
functioning as IL-4 antagonists and IL-13 antagonists, were
identified and isolated. The MAbs are designated 27A1, 5A1, and 63.
Another MAb, designated 1B7, was derived from MAb 63, and differs
from the parent antibody only in the light chain. 1B7 retains the
ability to bind IL-4R and to function as an IL-4 antagonist and an
IL-13 antagonist.
[0312] The DNA sequence of the variable region of the light chain
of MAb 27A1 is presented in SEQ ID NO:13, and the encoded amino
acid sequence is presented in SEQ ID NO:14. Complementarity
determining regions 1 to 3 (CDR 1-3) are believed to correspond to
amino acids 24-35, 51-57, and 90-99, of SEQ ID NO:14,
respectively.
[0313] The DNA sequence for the variable region of the heavy chain
of MAb 27A1 is presented as SEQ ID NO:15, and the encoded amino
acid sequence is presented in SEQ ID NO:16. Complementarity
determining regions 1 to 3 (CDR 1-3) are believed to correspond to
amino acids 31-35, 50-66, and 99-105, of SEQ ID NO:16,
respectively.
[0314] The DNA sequence of the variable region of the light chain
of MAb 5A1 is presented in SEQ ID NO:17, and the encoded amino acid
sequence is presented in SEQ ID NO:18. Complementarity determining
regions 1 to 3 (CDR 1-3) are believed to correspond to amino acids
24-34, 50-56, and 89-97 of SEQ ID NO:18, respectively.
[0315] The DNA sequence for the variable region of the heavy chain
of MAb 5A1 is presented as SEQ ID NO:19, and the encoded amino acid
sequence is presented in SEQ ID NO:20. Complementarity determining
regions 1 to 3 (CDR 1-3) are believed to correspond to amino acids
31-35, 50-65, and 98-112 of SEQ ID NO:20, respectively.
[0316] The DNA sequence of the variable region of the light chain
of MAb 63 is presented in SEQ ID NO:21, and the encoded amino acid
sequence is presented in SEQ ID NO:22. Complementarity determining
regions 1 to 3 (CDR 1-3) are believed to correspond to amino acids
24-34, 50-56, and 89-97 of SEQ ID NO:22, respectively.
[0317] The DNA sequence for the variable region of the heavy chain
of MAb 63 is presented as SEQ ID NO:23, and the encoded amino acid
sequence is presented in SEQ ID NO:24. Complementarity determining
regions 1 to 3 (CDR 1-3) are believed to correspond to amino acids
31-35, 50-66, and 99-106 of SEQ ID NO:24, respectively.
[0318] The DNA sequence of the variable region of the light chain
of MAb 1B7 is presented in SEQ ID NO:25, and the encoded amino acid
sequence is presented in SEQ ID NO:26. Complementarity determining
regions 1 to 3 (CDR 1-3) are believed to correspond to amino acids
24-34, 50-56, and 89-97 of SEQ ID NO:26, respectively.
[0319] MAb 1B7 was derived from MAb 63, and the heavy chains of the
two MAbs are identical. Thus, the DNA sequence for the variable
region of the heavy chain of MAb 1B7 is presented as SEQ ID NO:23,
and the encoded amino acid sequence is presented in SEQ ID NO:24.
Complementarity determining regions 1 to 3 (CDRs 1-3) are believed
to correspond to amino acids 31-35, 50-66, and 99-106 of SEQ ID
NO:24, respectively.
Sequence CWU 1
1
2612478DNAHomo sapiensCDS(1)..(2475)mat_peptide(76)..() 1atg ggg
tgg ctt tgc tct ggg ctc ctg ttc cct gtg agc tgc ctg gtc 48Met Gly
Trp Leu Cys Ser Gly Leu Leu Phe Pro Val Ser Cys Leu Val -25 -20 -15
-10 ctg ctg cag gtg gca agc tct ggg aac atg aag gtc ttg cag gag ccc
96Leu Leu Gln Val Ala Ser Ser Gly Asn Met Lys Val Leu Gln Glu Pro
-5 -1 1 5 acc tgc gtc tcc gac tac atg agc atc tct act tgc gag tgg
aag atg 144Thr Cys Val Ser Asp Tyr Met Ser Ile Ser Thr Cys Glu Trp
Lys Met 10 15 20 aat ggt ccc acc aat tgc agc acc gag ctc cgc ctg
ttg tac cag ctg 192Asn Gly Pro Thr Asn Cys Ser Thr Glu Leu Arg Leu
Leu Tyr Gln Leu 25 30 35 gtt ttt ctg ctc tcc gaa gcc cac acg tgt
atc cct gag aac aac gga 240Val Phe Leu Leu Ser Glu Ala His Thr Cys
Ile Pro Glu Asn Asn Gly 40 45 50 55 ggc gcg ggg tgc gtg tgc cac ctg
ctc atg gat gac gtg gtc agt gcg 288Gly Ala Gly Cys Val Cys His Leu
Leu Met Asp Asp Val Val Ser Ala 60 65 70 gat aac tat aca ctg gac
ctg tgg gct ggg cag cag ctg ctg tgg aag 336Asp Asn Tyr Thr Leu Asp
Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys 75 80 85 ggc tcc ttc aag
ccc agc gag cat gtg aaa ccc agg gcc cca gga aac 384Gly Ser Phe Lys
Pro Ser Glu His Val Lys Pro Arg Ala Pro Gly Asn 90 95 100 ctg aca
gtt cac acc aat gtc tcc gac act ctg ctg ctg acc tgg agc 432Leu Thr
Val His Thr Asn Val Ser Asp Thr Leu Leu Leu Thr Trp Ser 105 110 115
aac ccg tat ccc cct gac aat tac ctg tat aat cat ctc acc tat gca
480Asn Pro Tyr Pro Pro Asp Asn Tyr Leu Tyr Asn His Leu Thr Tyr Ala
120 125 130 135 gtc aac att tgg agt gaa aac gac ccg gca gat ttc aga
atc tat aac 528Val Asn Ile Trp Ser Glu Asn Asp Pro Ala Asp Phe Arg
Ile Tyr Asn 140 145 150 gtg acc tac cta gaa ccc tcc ctc cgc atc gca
gcc agc acc ctg aag 576Val Thr Tyr Leu Glu Pro Ser Leu Arg Ile Ala
Ala Ser Thr Leu Lys 155 160 165 tct ggg att tcc tac agg gca cgg gtg
agg gcc tgg gct cag tgc tat 624Ser Gly Ile Ser Tyr Arg Ala Arg Val
Arg Ala Trp Ala Gln Cys Tyr 170 175 180 aac acc acc tgg agt gag tgg
agc ccc agc acc aag tgg cac aac tcc 672Asn Thr Thr Trp Ser Glu Trp
Ser Pro Ser Thr Lys Trp His Asn Ser 185 190 195 tac agg gag ccc ttc
gag cag cac ctc ctg ctg ggc gtc agc gtt tcc 720Tyr Arg Glu Pro Phe
Glu Gln His Leu Leu Leu Gly Val Ser Val Ser 200 205 210 215 tgc att
gtc atc ctg gcc gtc tgc ctg ttg tgc tat gtc agc atc acc 768Cys Ile
Val Ile Leu Ala Val Cys Leu Leu Cys Tyr Val Ser Ile Thr 220 225 230
aag att aag aaa gaa tgg tgg gat cag att ccc aac cca gcc cgc agc
816Lys Ile Lys Lys Glu Trp Trp Asp Gln Ile Pro Asn Pro Ala Arg Ser
235 240 245 cgc ctc gtg gct ata ata atc cag gat gct cag ggg tca cag
tgg gag 864Arg Leu Val Ala Ile Ile Ile Gln Asp Ala Gln Gly Ser Gln
Trp Glu 250 255 260 aag cgg tcc cga ggc cag gaa cca gcc aag tgc cca
cac tgg aag aat 912Lys Arg Ser Arg Gly Gln Glu Pro Ala Lys Cys Pro
His Trp Lys Asn 265 270 275 tgt ctt acc aag ctc ttg ccc tgt ttt ctg
gag cac aac atg aaa agg 960Cys Leu Thr Lys Leu Leu Pro Cys Phe Leu
Glu His Asn Met Lys Arg 280 285 290 295 gat gaa gat cct cac aag gct
gcc aaa gag atg cct ttc cag ggc tct 1008Asp Glu Asp Pro His Lys Ala
Ala Lys Glu Met Pro Phe Gln Gly Ser 300 305 310 gga aaa tca gca tgg
tgc cca gtg gag atc agc aag aca gtc ctc tgg 1056Gly Lys Ser Ala Trp
Cys Pro Val Glu Ile Ser Lys Thr Val Leu Trp 315 320 325 cca gag agc
atc agc gtg gtg cga tgt gtg gag ttg ttt gag gcc ccg 1104Pro Glu Ser
Ile Ser Val Val Arg Cys Val Glu Leu Phe Glu Ala Pro 330 335 340 gtg
gag tgt gag gag gag gag gag gta gag gaa gaa aaa ggg agc ttc 1152Val
Glu Cys Glu Glu Glu Glu Glu Val Glu Glu Glu Lys Gly Ser Phe 345 350
355 tgt gca tcg cct gag agc agc agg gat gac ttc cag gag gga agg gag
1200Cys Ala Ser Pro Glu Ser Ser Arg Asp Asp Phe Gln Glu Gly Arg Glu
360 365 370 375 ggc att gtg gcc cgg cta aca gag agc ctg ttc ctg gac
ctg ctc gga 1248Gly Ile Val Ala Arg Leu Thr Glu Ser Leu Phe Leu Asp
Leu Leu Gly 380 385 390 gag gag aat ggg ggc ttt tgc cag cag gac atg
ggg gag tca tgc ctt 1296Glu Glu Asn Gly Gly Phe Cys Gln Gln Asp Met
Gly Glu Ser Cys Leu 395 400 405 ctt cca cct tcg gga agt acg agt gct
cac atg ccc tgg gat gag ttc 1344Leu Pro Pro Ser Gly Ser Thr Ser Ala
His Met Pro Trp Asp Glu Phe 410 415 420 cca agt gca ggg ccc aag gag
gca cct ccc tgg ggc aag gag cag cct 1392Pro Ser Ala Gly Pro Lys Glu
Ala Pro Pro Trp Gly Lys Glu Gln Pro 425 430 435 ctc cac ctg gag cca
agt cct cct gcc agc ccg acc cag agt cca gac 1440Leu His Leu Glu Pro
Ser Pro Pro Ala Ser Pro Thr Gln Ser Pro Asp 440 445 450 455 aac ctg
act tgc aca gag acg ccc ctc gtc atc gca ggc aac cct gct 1488Asn Leu
Thr Cys Thr Glu Thr Pro Leu Val Ile Ala Gly Asn Pro Ala 460 465 470
tac cgc agc ttc agc aac tcc ctg agc cag tca ccg tgt ccc aga gag
1536Tyr Arg Ser Phe Ser Asn Ser Leu Ser Gln Ser Pro Cys Pro Arg Glu
475 480 485 ctg ggt cca gac cca ctg ctg gcc aga cac ctg gag gaa gta
gaa ccc 1584Leu Gly Pro Asp Pro Leu Leu Ala Arg His Leu Glu Glu Val
Glu Pro 490 495 500 gag atg ccc tgt gtc ccc cag ctc tct gag cca acc
act gtg ccc caa 1632Glu Met Pro Cys Val Pro Gln Leu Ser Glu Pro Thr
Thr Val Pro Gln 505 510 515 cct gag cca gaa acc tgg gag cag atc ctc
cgc cga aat gtc ctc cag 1680Pro Glu Pro Glu Thr Trp Glu Gln Ile Leu
Arg Arg Asn Val Leu Gln 520 525 530 535 cat ggg gca gct gca gcc ccc
gtc tcg gcc ccc acc agt ggc tat cag 1728His Gly Ala Ala Ala Ala Pro
Val Ser Ala Pro Thr Ser Gly Tyr Gln 540 545 550 gag ttt gta cat gcg
gtg gag cag ggt ggc acc cag gcc agt gcg gtg 1776Glu Phe Val His Ala
Val Glu Gln Gly Gly Thr Gln Ala Ser Ala Val 555 560 565 gtg ggc ttg
ggt ccc cca gga gag gct ggt tac aag gcc ttc tca agc 1824Val Gly Leu
Gly Pro Pro Gly Glu Ala Gly Tyr Lys Ala Phe Ser Ser 570 575 580 ctg
ctt gcc agc agt gct gtg tcc cca gag aaa tgt ggg ttt ggg gct 1872Leu
Leu Ala Ser Ser Ala Val Ser Pro Glu Lys Cys Gly Phe Gly Ala 585 590
595 agc agt ggg gaa gag ggg tat aag cct ttc caa gac ctc att cct ggc
1920Ser Ser Gly Glu Glu Gly Tyr Lys Pro Phe Gln Asp Leu Ile Pro Gly
600 605 610 615 tgc cct ggg gac cct gcc cca gtc cct gtc ccc ttg ttc
acc ttt gga 1968Cys Pro Gly Asp Pro Ala Pro Val Pro Val Pro Leu Phe
Thr Phe Gly 620 625 630 ctg gac agg gag cca cct cgc agt ccg cag agc
tca cat ctc cca agc 2016Leu Asp Arg Glu Pro Pro Arg Ser Pro Gln Ser
Ser His Leu Pro Ser 635 640 645 agc tcc cca gag cac ctg ggt ctg gag
ccg ggg gaa aag gta gag gac 2064Ser Ser Pro Glu His Leu Gly Leu Glu
Pro Gly Glu Lys Val Glu Asp 650 655 660 atg cca aag ccc cca ctt ccc
cag gag cag gcc aca gac ccc ctt gtg 2112Met Pro Lys Pro Pro Leu Pro
Gln Glu Gln Ala Thr Asp Pro Leu Val 665 670 675 gac agc ctg ggc agt
ggc att gtc tac tca gcc ctt acc tgc cac ctg 2160Asp Ser Leu Gly Ser
Gly Ile Val Tyr Ser Ala Leu Thr Cys His Leu 680 685 690 695 tgc ggc
cac ctg aaa cag tgt cat ggc cag gag gat ggt ggc cag acc 2208Cys Gly
His Leu Lys Gln Cys His Gly Gln Glu Asp Gly Gly Gln Thr 700 705 710
cct gtc atg gcc agt cct tgc tgt ggc tgc tgc tgt gga gac agg tcc
2256Pro Val Met Ala Ser Pro Cys Cys Gly Cys Cys Cys Gly Asp Arg Ser
715 720 725 tcg ccc cct aca acc ccc ctg agg gcc cca gac ccc tct cca
ggt ggg 2304Ser Pro Pro Thr Thr Pro Leu Arg Ala Pro Asp Pro Ser Pro
Gly Gly 730 735 740 gtt cca ctg gag gcc agt ctg tgt ccg gcc tcc ctg
gca ccc tcg ggc 2352Val Pro Leu Glu Ala Ser Leu Cys Pro Ala Ser Leu
Ala Pro Ser Gly 745 750 755 atc tca gag aag agt aaa tcc tca tca tcc
ttc cat cct gcc cct ggc 2400Ile Ser Glu Lys Ser Lys Ser Ser Ser Ser
Phe His Pro Ala Pro Gly 760 765 770 775 aat gct cag agc tca agc cag
acc ccc aaa atc gtg aac ttt gtc tcc 2448Asn Ala Gln Ser Ser Ser Gln
Thr Pro Lys Ile Val Asn Phe Val Ser 780 785 790 gtg gga ccc aca tac
atg agg gtc tct tat 2478Val Gly Pro Thr Tyr Met Arg Val Ser 795 800
2825PRTHomo sapiens 2Met Gly Trp Leu Cys Ser Gly Leu Leu Phe Pro
Val Ser Cys Leu Val -25 -20 -15 -10 Leu Leu Gln Val Ala Ser Ser Gly
Asn Met Lys Val Leu Gln Glu Pro -5 -1 1 5 Thr Cys Val Ser Asp Tyr
Met Ser Ile Ser Thr Cys Glu Trp Lys Met 10 15 20 Asn Gly Pro Thr
Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu 25 30 35 Val Phe
Leu Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly 40 45 50 55
Gly Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala 60
65 70 Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp
Lys 75 80 85 Gly Ser Phe Lys Pro Ser Glu His Val Lys Pro Arg Ala
Pro Gly Asn 90 95 100 Leu Thr Val His Thr Asn Val Ser Asp Thr Leu
Leu Leu Thr Trp Ser 105 110 115 Asn Pro Tyr Pro Pro Asp Asn Tyr Leu
Tyr Asn His Leu Thr Tyr Ala 120 125 130 135 Val Asn Ile Trp Ser Glu
Asn Asp Pro Ala Asp Phe Arg Ile Tyr Asn 140 145 150 Val Thr Tyr Leu
Glu Pro Ser Leu Arg Ile Ala Ala Ser Thr Leu Lys 155 160 165 Ser Gly
Ile Ser Tyr Arg Ala Arg Val Arg Ala Trp Ala Gln Cys Tyr 170 175 180
Asn Thr Thr Trp Ser Glu Trp Ser Pro Ser Thr Lys Trp His Asn Ser 185
190 195 Tyr Arg Glu Pro Phe Glu Gln His Leu Leu Leu Gly Val Ser Val
Ser 200 205 210 215 Cys Ile Val Ile Leu Ala Val Cys Leu Leu Cys Tyr
Val Ser Ile Thr 220 225 230 Lys Ile Lys Lys Glu Trp Trp Asp Gln Ile
Pro Asn Pro Ala Arg Ser 235 240 245 Arg Leu Val Ala Ile Ile Ile Gln
Asp Ala Gln Gly Ser Gln Trp Glu 250 255 260 Lys Arg Ser Arg Gly Gln
Glu Pro Ala Lys Cys Pro His Trp Lys Asn 265 270 275 Cys Leu Thr Lys
Leu Leu Pro Cys Phe Leu Glu His Asn Met Lys Arg 280 285 290 295 Asp
Glu Asp Pro His Lys Ala Ala Lys Glu Met Pro Phe Gln Gly Ser 300 305
310 Gly Lys Ser Ala Trp Cys Pro Val Glu Ile Ser Lys Thr Val Leu Trp
315 320 325 Pro Glu Ser Ile Ser Val Val Arg Cys Val Glu Leu Phe Glu
Ala Pro 330 335 340 Val Glu Cys Glu Glu Glu Glu Glu Val Glu Glu Glu
Lys Gly Ser Phe 345 350 355 Cys Ala Ser Pro Glu Ser Ser Arg Asp Asp
Phe Gln Glu Gly Arg Glu 360 365 370 375 Gly Ile Val Ala Arg Leu Thr
Glu Ser Leu Phe Leu Asp Leu Leu Gly 380 385 390 Glu Glu Asn Gly Gly
Phe Cys Gln Gln Asp Met Gly Glu Ser Cys Leu 395 400 405 Leu Pro Pro
Ser Gly Ser Thr Ser Ala His Met Pro Trp Asp Glu Phe 410 415 420 Pro
Ser Ala Gly Pro Lys Glu Ala Pro Pro Trp Gly Lys Glu Gln Pro 425 430
435 Leu His Leu Glu Pro Ser Pro Pro Ala Ser Pro Thr Gln Ser Pro Asp
440 445 450 455 Asn Leu Thr Cys Thr Glu Thr Pro Leu Val Ile Ala Gly
Asn Pro Ala 460 465 470 Tyr Arg Ser Phe Ser Asn Ser Leu Ser Gln Ser
Pro Cys Pro Arg Glu 475 480 485 Leu Gly Pro Asp Pro Leu Leu Ala Arg
His Leu Glu Glu Val Glu Pro 490 495 500 Glu Met Pro Cys Val Pro Gln
Leu Ser Glu Pro Thr Thr Val Pro Gln 505 510 515 Pro Glu Pro Glu Thr
Trp Glu Gln Ile Leu Arg Arg Asn Val Leu Gln 520 525 530 535 His Gly
Ala Ala Ala Ala Pro Val Ser Ala Pro Thr Ser Gly Tyr Gln 540 545 550
Glu Phe Val His Ala Val Glu Gln Gly Gly Thr Gln Ala Ser Ala Val 555
560 565 Val Gly Leu Gly Pro Pro Gly Glu Ala Gly Tyr Lys Ala Phe Ser
Ser 570 575 580 Leu Leu Ala Ser Ser Ala Val Ser Pro Glu Lys Cys Gly
Phe Gly Ala 585 590 595 Ser Ser Gly Glu Glu Gly Tyr Lys Pro Phe Gln
Asp Leu Ile Pro Gly 600 605 610 615 Cys Pro Gly Asp Pro Ala Pro Val
Pro Val Pro Leu Phe Thr Phe Gly 620 625 630 Leu Asp Arg Glu Pro Pro
Arg Ser Pro Gln Ser Ser His Leu Pro Ser 635 640 645 Ser Ser Pro Glu
His Leu Gly Leu Glu Pro Gly Glu Lys Val Glu Asp 650 655 660 Met Pro
Lys Pro Pro Leu Pro Gln Glu Gln Ala Thr Asp Pro Leu Val 665 670 675
Asp Ser Leu Gly Ser Gly Ile Val Tyr Ser Ala Leu Thr Cys His Leu 680
685 690 695 Cys Gly His Leu Lys Gln Cys His Gly Gln Glu Asp Gly Gly
Gln Thr 700 705 710 Pro Val Met Ala Ser Pro Cys Cys Gly Cys Cys Cys
Gly Asp Arg Ser 715 720 725 Ser Pro Pro Thr Thr Pro Leu Arg Ala Pro
Asp Pro Ser Pro Gly Gly 730 735 740 Val Pro Leu Glu Ala Ser Leu Cys
Pro Ala Ser Leu Ala Pro Ser Gly 745 750 755 Ile Ser Glu Lys Ser Lys
Ser Ser Ser Ser Phe His Pro Ala Pro Gly 760 765 770 775 Asn Ala Gln
Ser Ser Ser Gln Thr Pro Lys Ile Val Asn Phe Val Ser 780 785 790 Val
Gly Pro Thr Tyr Met Arg Val Ser 795 800 38PRTArtificialFLAG peptide
3Asp Tyr Lys Asp Asp Asp Asp Lys 1 5 43159DNAArtificial"Cloning
vector pGP1k" 4aattagcggc cgctgtcgac aagcttcgaa ttcagtatcg
atgtggggta cctactgtcc 60cgggattgcg gatccgcgat gatatcgttg atcctcgagt
gcggccgcag tatgcaaaaa 120aaagcccgct cattaggcgg gctcttggca
gaacatatcc atcgcgtccg ccatctccag
180cagccgcacg cggcgcatct cgggcagcgt tgggtcctgg ccacgggtgc
gcatgatcgt 240gctcctgtcg ttgaggaccc ggctaggctg gcggggttgc
cttactggtt agcagaatga 300atcaccgata cgcgagcgaa cgtgaagcga
ctgctgctgc aaaacgtctg cgacctgagc 360aacaacatga atggtcttcg
gtttccgtgt ttcgtaaagt ctggaaacgc ggaagtcagc 420gccctgcacc
attatgttcc ggatctgcat cgcaggatgc tgctggctac cctgtggaac
480acctacatct gtattaacga agcgctggca ttgaccctga gtgatttttc
tctggtcccg 540ccgcatccat accgccagtt gtttaccctc acaacgttcc
agtaaccggg catgttcatc 600atcagtaacc cgtatcgtga gcatcctctc
tcgtttcatc ggtatcatta cccccatgaa 660cagaaattcc cccttacacg
gaggcatcaa gtgaccaaac aggaaaaaac cgcccttaac 720atggcccgct
ttatcagaag ccagacatta acgcttctgg agaaactcaa cgagctggac
780gcggatgaac aggcagacat ctgtgaatcg cttcacgacc acgctgatga
gctttaccgc 840agctgcctcg cgcgtttcgg tgatgacggt gaaaacctct
gacacatgca gctcccggag 900acggtcacag cttgtctgta agcggatgcc
gggagcagac aagcccgtca gggcgcgtca 960gcgggtgttg gcgggtgtcg
gggcgcagcc atgacccagt cacgtagcga tagcggagtg 1020tatactggct
taactatgcg gcatcagagc agattgtact gagagtgcac catatgcggt
1080gtgaaatacc gcacagatgc gtaaggagaa aataccgcat caggcgctct
tccgcttcct 1140cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg
agcggtatca gctcactcaa 1200aggcggtaat acggttatcc acagaatcag
gggataacgc aggaaagaac atgtgagcaa 1260aaggccagca aaaggccagg
aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc 1320tccgcccccc
tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga
1380caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc
tctcctgttc 1440cgaccctgcc gcttaccgga tacctgtccg cctttctccc
ttcgggaagc gtggcgcttt 1500ctcatagctc acgctgtagg tatctcagtt
cggtgtaggt cgttcgctcc aagctgggct 1560gtgtgcacga accccccgtt
cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 1620agtccaaccc
ggtaagacac gacttatcgc cactggcagc agccaggcgc gccttggcct
1680aagaggccac tggtaacagg attagcagag cgaggtatgt aggcggtgct
acagagttct 1740tgaagtggtg gcctaactac ggctacacta gaaggacagt
atttggtatc tgcgctctgc 1800tgaagccagt taccttcgga aaaagagttg
gtagctcttg atccggcaaa caaaccaccg 1860ctggtagcgg tggttttttt
gtttgcaagc agcagattac gcgcagaaaa aaaggatctc 1920aagaagatcc
tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt
1980aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt
ttaaattaaa 2040aatgaagttt taaatcaatc taaagtatat atgagtaaac
ttggtctgac agttaccaat 2100gcttaatcag tgaggcacct atctcagcga
tctgtctatt tcgttcatcc atagttgcct 2160gactccccgt cgtgtagata
actacgatac gggagggctt accatctggc cccagtgctg 2220caatgatacc
gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag
2280ccggaagggc cgagcgcaga agtggtcctg caactttatc cgcctccatc
cagtctatta 2340attgttgccg ggaagctaga gtaagtagtt cgccagttaa
tagtttgcgc aacgttgttg 2400ccattgctgc aggcatcgtg gtgtcacgct
cgtcgtttgg tatggcttca ttcagctccg 2460gttcccaacg atcaaggcga
gttacatgat cccccatgtt gtgcaaaaaa gcggttagct 2520ccttcggtcc
tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta
2580tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt
tctgtgactg 2640gtgagtactc aaccaagtca ttctgagaat agtgtatgcg
gcgaccgagt tgctcttgcc 2700cggcgtcaac acgggataat accgcgccac
atagcagaac tttaaaagtg ctcatcattg 2760gaaaacgttc ttcggggcga
aaactctcaa ggatcttacc gctgttgaga tccagttcga 2820tgtaacccac
tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg
2880ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg
acacggaaat 2940gttgaatact catactcttc ctttttcaat attattgaag
catttatcag ggttattgtc 3000tcatgagcgg atacatattt gaatgtattt
agaaaaataa acaaataggg gttccgcgca 3060catttccccg aaaagtgcca
cctgacgtct aagaaaccat tattatcatg acattaacct 3120ataaaaatag
gcgtatcacg aggccctttc gtcttcaag 31595321DNAHomo
sapiensCDS(1)..(321) 5gaa att gtg ttg acg cag tct cca ggc acc ctg
tct ttg tct cca ggg 48Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu
Ser Leu Ser Pro Gly 1 5 10 15 gaa aga gcc acc ctc tcc tgc agg gcc
agt cag agt gtt agc acc agc 96Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Thr Ser 20 25 30 tac tta gcc tgg tac cag cag
aaa cct ggc cag gct ccc agg ctc ctc 144Tyr Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 atc tat ggt gca tcc
agc agg gcc act ggc atc cca gac agg ttc agt 192Ile Tyr Gly Ala Ser
Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 ggc agt ggg
tct ggg aca gac ttc act ctc acc atc agc aga ctg gag 240Gly Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 cct
gaa gat ttt gca gtg tat tac tgt cag cag tat ggt agt tca ccg 288Pro
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90
95 acg ttc ggc caa ggg acc aag gtg gaa atc aaa 321Thr Phe Gly Gln
Gly Thr Lys Val Glu Ile Lys 100 105 6107PRTHomo sapiens 6Glu Ile
Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 20
25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp
Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 105 7354DNAHomo sapiensCDS(1)..(354) 7cag gtg
cag ctg gtg gag tct ggg gga ggc gtg gtc cag cct ggg agg 48Gln Val
Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15
tcc ctg aga ctc tcc tgt gca gcc tct gga ttc gcc ttc agt agc tat
96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr
20 25 30 gct att cag tgg gtc cgc cag gct cca ggc aag ggg ctg gag
tgg gtg 144Ala Ile Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45 gca gtt ata tca tat gat gga agc aag aaa tac tat
gca gac tcc gtg 192Ala Val Ile Ser Tyr Asp Gly Ser Lys Lys Tyr Tyr
Ala Asp Ser Val 50 55 60 aag ggc cga ttc acc atc tcc aga gac aat
tcc aag aat acg ctg tat 240Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ser Lys Asn Thr Leu Tyr 65 70 75 80 ttg caa atg aac agc ctg aga gct
gag gac acg gct gtg tat tac tgt 288Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 gcg aga gag ggg aga cgt
ggg tcg ttt gac tac tgg ggc cag gga acc 336Ala Arg Glu Gly Arg Arg
Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 ctg gtc acc gtc
tcc tca 354Leu Val Thr Val Ser Ser 115 8118PRTHomo sapiens 8Gln Val
Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr 20
25 30 Ala Ile Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Lys Lys Tyr Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Gly Arg Arg Gly
Ser Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser
Ser 115 9327DNAHomo sapiensCDS(1)..(327) 9gaa att gtg ttg acg cag
tct cca ggc acc ctg tct ttg tct cca ggg 48Glu Ile Val Leu Thr Gln
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 gaa aga gcc acc
ctc tcc tgc agg gcc agt cag agt gtt agc agc agc 96Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 tac tta
gcc tgg tac cag cag aaa cct ggc cag gct ccc agg ctc ctc 144Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45
atc ttt ggt gca tcc agc agg gcc act ggc atc cca gac agg ttc agt
192Ile Phe Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60 ggc agt ggg tct ggg aca gac ttc act ctc acc atc agc aga
ctg gag 240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
Leu Glu 65 70 75 80 cct gaa gat ttt gca gtg tat tac tgt cag cag tat
ggt agc tca cct 288Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
Gly Ser Ser Pro 85 90 95 ccg tgg acg ttc ggc caa ggg acc aag gtg
gaa atc aaa 327Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 10109PRTHomo sapiens 10Glu Ile Val Leu Thr Gln Ser Pro Gly
Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys
Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Phe Gly
Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70
75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser
Pro 85 90 95 Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 11345DNAHomo sapiensCDS(1)..(345) 11gag gtt cag ctg gtg cag
tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly 1 5 10 15 tcc ctg aga ctc
tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu Arg Leu
Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30 gct atg
ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala Met
Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
tca ggt att ggt act ggt ggt gcc aca aac tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60 ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg
tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu 65 70 75 80 caa atg aac agc ctg aga gcc gag gac atg gct gtg
tat tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val
Tyr Tyr Cys Ala 85 90 95 aga ggg agg tac tac ttt gac tac tgg ggc
cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Tyr Phe Asp Tyr Trp Gly
Gln Gly Thr Leu Val Thr 100 105 110 gtc tcc tca 345Val Ser Ser 115
12115PRTHomo sapiens 12Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu
Val His Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Gly Ser
Gly Phe Thr Phe Ser Arg Asn 20 25 30 Ala Met Phe Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Gly Thr
Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln
Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90
95 Arg Gly Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110 Val Ser Ser 115 13327DNAHomo sapiensCDS(1)..(327) 13gaa
att gtg ttg acg cag tct cca ggc acc ctg tct ttg tct cca ggg 48Glu
Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10
15 gaa aga gcc acc ctc tcc tgc agg gcc agt cag agt gtt agc agc agc
96Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30 tac tta gcc tgg tac caa cag aaa cct ggc cag gct ccc agg
ctc ctc 144Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
Leu Leu 35 40 45 atc tat ggt gca tcc agc agg gcc act ggc atc cca
gac agg ttc agt 192Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro
Asp Arg Phe Ser 50 55 60 ggc agt ggg tct ggg aca gac ttc act ctc
acc atc agc aga ctg gag 240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Arg Leu Glu 65 70 75 80 cct gaa gat ttt gca gtg tat tac
tgt cag cag tat ggt agc tca cct 288Pro Glu Asp Phe Ala Val Tyr Tyr
Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 ccg tgg acg ttc ggc caa
ggg acc aag gtg gaa atc aaa 327Pro Trp Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 105 14109PRTHomo sapiens 14Glu Ile Val Leu Thr
Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40
45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
Gly Ser Ser Pro 85 90 95 Pro Trp Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys 100 105 15348DNAHomo sapiensCDS(1)..(348) 15cag gtg cag
ctg gtg gag tct ggg gga ggc gtg gtc cag cct ggg agg 48Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 tcc
ctg aga ctc tcc tgt tca gcg tct gga ttc acc ttc agt aga tat 96Ser
Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Arg Tyr 20 25
30 ggc atg cac tgg gtc cgc cag gct cca ggc agg ggg ctg gag tgg gtg
144Gly Met His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val
35 40 45 gca att ata tgg ttt gaa gga aat aat caa tac tat gca gac
tcc gtg 192Ala Ile Ile Trp Phe Glu Gly Asn Asn Gln Tyr Tyr Ala Asp
Ser Val 50 55 60 aag ggc cga ttc acc gtc tcc aga gac aat tcc aag
aac acg ctg tat 240Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr 65 70 75 80 ctg gaa atg aac agc ctg aga gcc gag gac
acg gct gtg tat tac tgt 288Leu Glu Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 gcg aga ggg aag tac tac ttt gac
tac tgg ggc cag gga acc ctg gtc 336Ala Arg Gly Lys Tyr Tyr Phe Asp
Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 acc gtc tcc tca 348Thr
Val Ser Ser 115 16116PRTHomo sapiens 16Gln Val Gln Leu Val Glu Ser
Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10
15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Arg Tyr
20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu
Trp Val 35 40 45 Ala Ile Ile Trp Phe Glu Gly Asn Asn Gln Tyr Tyr
Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn
Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Lys Tyr Tyr
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser
115 17321DNAHomo sapiensCDS(1)..(321) 17gaa att gtg ttg aca cag tct
cca gcc acc ctg tct ttg tct cca ggg 48Glu Ile Val Leu Thr Gln Ser
Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 gaa aga gcc acc ctc
tcc tgc agg gcc agt cag agt gtt agc agc tac 96Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 tta gcc tgg
tac caa cag aaa cct ggc cag gct ccc agg ctc ctc atc 144Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 tat
cat gca tcc aac agg gcc act ggc atc cca gcc agg ttc agt ggc 192Tyr
His Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55
60 agt ggg tct ggg aca gac ttc act ctc acc atc agc agc cta gag cct
240Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80 gaa gat ttt gca gtt tat tac tgt cag cag cgt agc aac tgg
cct ctc 288Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp
Pro Leu 85 90 95 act ttc ggc gga ggg acc aag gtg gag atc aaa 321Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 18107PRTHomo
sapiens 18Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser
Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
Ala Pro Arg Leu Leu Ile 35 40 45 Tyr His Ala Ser Asn Arg Ala Thr
Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala
Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 85 90 95 Thr Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 19369DNAHomo
sapiensCDS(1)..(369) 19gag gtg caa ctg gtg cag tct ggg gga ggc ttg
gta cat cct ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu
Val His Pro Gly Gly 1 5 10 15 tcc ctg aga ctc acc tgt gca ggc tct
gga ttc acc ttc agt aac ttt 96Ser Leu Arg Leu Thr Cys Ala Gly Ser
Gly Phe Thr Phe Ser Asn Phe 20 25 30 gtt atg cac tgg gtt cgc cag
act cca gga caa ggt ctg gag tgg gtt 144Val Met His Trp Val Arg Gln
Thr Pro Gly Gln Gly Leu Glu Trp Val 35 40 45 tca gct att ggt act
ggt ggt ggc aca tac tat gca gac tcc gtg aag 192Ser Ala Ile Gly Thr
Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys 50 55 60 ggc cga ttc
acc atc tcc aga gac aat gcc aag agc tcc tta tat ctt 240Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr Leu 65 70 75 80 caa
atg aac agc ctg aga gcc gag gac atg gct gtg tat tac tgt gca 288Gln
Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90
95 aga gat cgg cct atg gtt cgg gga gtc att ata gac tac ttt gac tac
336Arg Asp Arg Pro Met Val Arg Gly Val Ile Ile Asp Tyr Phe Asp Tyr
100 105 110 tgg ggc cag gga acc ctg gtc acc gtc tcc tca 369Trp Gly
Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 20123PRTHomo sapiens
20Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Thr Cys Ala Gly Ser Gly Phe Thr Phe Ser Asn
Phe 20 25 30 Val Met His Trp Val Arg Gln Thr Pro Gly Gln Gly Leu
Glu Trp Val 35 40 45 Ser Ala Ile Gly Thr Gly Gly Gly Thr Tyr Tyr
Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Ser Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala
Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Arg Pro Met
Val Arg Gly Val Ile Ile Asp Tyr Phe Asp Tyr 100 105 110 Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser 115 120 21321DNAHomo
sapiensCDS(1)..(321) 21gac atc cag atg acc cag tct cca tct tcc gtg
tct gca tct gta gga 48Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
Ser Ala Ser Val Gly 1 5 10 15 gac aga gtc acc atc act tgt cgg gcg
agt cag ggt att agc acc tgg 96Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Thr Trp 20 25 30 tta gcc tgg tat cag cat aaa
cca ggg aaa gcc cct aag ctc ctg atc 144Leu Ala Trp Tyr Gln His Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 tat gtt gca tcc agt
ttg caa agt ggg gtc cca tca agg ttc agc ggc 192Tyr Val Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 agt gga tct
ggg aca gat ttc act ctc acc atc agc agc ctg cag cct 240Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 gaa
gat ttt gca act tac tat tgt caa cag gct aat agt ttc cca ttc 288Glu
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Phe 85 90
95 act ttc ggc cct ggg acc aaa gtg gat atc aaa 321Thr Phe Gly Pro
Gly Thr Lys Val Asp Ile Lys 100 105 22107PRTHomo sapiens 22Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Trp 20
25 30 Leu Ala Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Val Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Ala Asn Ser Phe Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys
Val Asp Ile Lys 100 105 23351DNAHomo sapiensCDS(1)..(351) 23gag gtg
cag gtg ttg gag tcg ggg gga aac ttg gta cag cct ggg ggg 48Glu Val
Gln Val Leu Glu Ser Gly Gly Asn Leu Val Gln Pro Gly Gly 1 5 10 15
tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt agc agc tat
96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30 gcc atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag
tgg gtc 144Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45 tct tct att act ggt agt ggg ggt agc aca tac tac
gca gac tcc gtg 192Ser Ser Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr
Ala Asp Ser Val 50 55 60 aag ggc cgg ttc acc atc tcc aga gac aat
tcc aag aac acg ctg tat 240Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ser Lys Asn Thr Leu Tyr 65 70 75 80 ctg caa atg aac agc ctg aga gcc
gag gac acg gcc att ttt tac tgt 288Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Ile Phe Tyr Cys 85 90 95 gcg aaa gat aac cgg gga
ttc ttt cac tat tgg ggc cag gga acc ctg 336Ala Lys Asp Asn Arg Gly
Phe Phe His Tyr Trp Gly Gln Gly Thr Leu 100 105 110 gtc acc gtc tcc
tca 351Val Thr Val Ser Ser 115 24117PRTHomo sapiens 24Glu Val Gln
Val Leu Glu Ser Gly Gly Asn Leu Val Gln Pro Gly Gly 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25
30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ser Ser Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Ile Phe Tyr Cys 85 90 95 Ala Lys Asp Asn Arg Gly Phe Phe
His Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115
25321DNAHomo sapiensCDS(1)..(321) 25gaa att gtg ttg aca cag tct cca
tct tcc gtg tct gca tct gta gga 48Glu Ile Val Leu Thr Gln Ser Pro
Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 gac aga gtc acc atc act
tgt cgg gcg agt cag ggt att agc aat cgg 96Asp Arg Val Thr Ile Thr
Cys Arg Ala Ser Gln Gly Ile Ser Asn Arg 20 25 30 tta gcc tgg tat
cag cag aaa cca gga aaa gcc cct aaa ctc ctc atc 144Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 tat att
gca tcc att ttg caa agg ggg gtc cca tca aga ttc agc ggc 192Tyr Ile
Ala Ser Ile Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly 50 55 60
agt gga tct ggg aca gat ttc act ctc acc atc acc agg ctg cag cct
240Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Gln Pro
65 70 75 80 gaa gat ttt gca acc tac tat tgt caa cag gca aac agt ttc
cca ttc 288Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe
Pro Phe 85 90 95 act ttc ggc cct ggg acc aaa gtg gat atc aaa 321Thr
Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 26107PRTHomo
sapiens 26Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Ser Asn Arg 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ile Ala Ser Ile Leu Gln Arg
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Thr Arg Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Phe 85 90 95 Thr Phe
Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105
* * * * *